Skip over navigation
Outline
Indent Level
Color Curly Brackets (indicating CPC extensions to IPC) References Date Revised
Search Symbol
CPC
COOPERATIVE PATENT CLASSIFICATION
Collapse
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N 63/00 ; food compositions A21 , A23 ; medicinal preparations A61K ; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L ; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N 1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q) [2014‑11]
NOTE
-
Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes.


Attention is drawn to Notes (1) to (3) following the title of Class C12 .

When classifying in this group, classification is also made in group B01D 15/08 insofar as subject matter of general interest relating to chromatography is concerned.


WARNING
-
The following IPC groups are not used in the CPC scheme. Subject matter covered by these groups is classified in the following CPC groups:

C12N1/11 covered by C12N 15/79
C12N1/13 covered by C12N 15/79
C12N1/15 covered by C12N 15/80
C12N1/19 covered by C12N 15/81
C12N1/21 covered by C12N 15/74
C12N5/02 covered by C12N 5/00, C12N 5/04 to C12N 5/166
C12N5/07 - C12N5/095 covered by C12N 5/06 and subgroups
C12N5/18 - C12N5/28 covered by C12N 5/16 and subgroups
C12N5/08 covered by C12N 5/06 to C12N5/06R
C12N5/18 covered by C12N 5/16
C12N5/20 covered by C12N 5/163
C12N5/22 covered by C12N 5/16
C12N5/24 covered by C12N 5/163
C12N5/26 covered by C12N 5/166
C12N5/28 covered by C12N 5/166
C12N7/01 covered by C12N 7/00
C12N9/26 covered by C12N 9/2408
C12N9/38 covered by C12N 9/2468
C12N9/42 covered by C12N 9/2434
C12N9/44 covered by C12N 9/2451
C12N9/70 covered by C07K 14/3153
C12N15/05 covered by C12N 5/14
C12N15/06 covered by C12N 5/16
C12N15/07 covered by C12N 5/16
C12N15/08 covered by C12N 5/166
C12N15/12 covered by C07K 14/435
C12N15/13 covered by C07K 16/00
C12N15/14 covered by C07K 14/765
C12N15/15 covered by C07K 14/81
C12N15/16 covered by C07K 14/575
C12N15/17 covered by C07K 14/62
C12N15/18 covered by C07K 14/61
C12N15/19 covered by C07K 14/52
C12N15/20 covered by C07K 14/555
C12N15/21 covered by C07K 14/56
C12N15/22 covered by C07K 14/565
C12N15/23 covered by C07K 14/57
C12N15/24 covered by C07K 14/54
C12N15/25 covered by C07K 14/545
C12N15/26 covered by C07K 14/55
C12N15/27 covered by C07K 14/53
C12N15/28 covered by C07K 14/525
C12N15/29 covered by C07K 14/415
C12N15/30 covered by C07K 14/44
C12N15/31 covered by C07K 14/195, C07K 14/005
C12N15/32 covered by C07K 14/325
C12N15/33 covered by C07K 14/005
C12N15/34 covered by C07K 14/01
C12N15/35 covered by C07K 14/015
C12N15/36 covered by C07K 14/02
C12N15/37 covered by C07K 14/025
C12N15/38 covered by C07K 14/03
C12N15/39 covered by C07K 14/065
C12N15/40 covered by C07K 14/08
C12N15/41 covered by C07K 14/085
C12N15/42 covered by C07K 14/09
C12N15/43 covered by C07K 14/105
C12N15/44 covered by C07K 14/11
C12N15/45 covered by C07K 14/115
C12N15/46 covered by C07K 14/14
C12N15/47 covered by C07K 14/145
C12N15/48 covered by C07K 14/15
C12N15/49 covered by C07K 14/155
C12N15/50 covered by C07K 14/165
C12N15/51 covered by C07K 14/02, C07K 14/10, C07K 14/18
C12N15/53 covered by C12N9/02
C12N15/54 covered by C12N 9/10
C12N15/55 covered by C12N 9/14
C12N15/56 covered by C12N 9/24
C12N15/57 covered by C12N 9/48
C12N15/58 covered by C12N 9/6456
C12N15/59 covered by C12N 9/6483
C12N15/60 covered by C12N 9/88
C12N15/61 covered by C12N 9/90
C12N15/83 covered by C12N 15/82
C12N15/84 covered by C12N 15/82


Collapse
Micro-organisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from micro-organisms A61K 35/66 ; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines A61K 39/00); Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor [2013‑01]
C12N 1/005
.
{
after treatment of microbial biomass not covered by C12N 1/02 to C12N 1/08
}
[2013‑01]
C12N 1/02
.
Separating micro-organisms from their culture media [2013‑01]
.
Preserving or maintaining viable micro-organisms (immobilised micro-organisms C12N 11/00) [2013‑01]
Collapse
C12N 1/06
.
Lysis of micro-organisms [2013‑01]
C12N 1/063
. .
{
of yeast
}
[2013‑01]
C12N 1/066
. .
{
by physical methods
}
[2013‑01]
C12N 1/08
.
Reducing the nucleic acid content [2013‑01]
.
Protozoa; Culture media therefor [2013‑01]
.
Unicellular algae; Culture media therefor (culture of multi-cellular plants A01G ; as new plants A01H 13/00) [2013‑01]
Collapse
.
Fungi (culture of mushrooms A01G 1/04 ; as new plants per se A01H 15/00 ;
{
fungi per se C12R 1/645 to C12R 1/885
}
)
Culture media therefor [2013‑01]
Collapse
C12N 1/16
. .
Yeasts; Culture media therefor [2013‑01]
C12N 1/18
. . .
Baker`s yeast; Brewer`s yeast [2013‑01]
.
Bacteria
{
(bacteria per se C12R 1/01 to C12R 1/64)
}
; Culture media therefor [2013‑01]
C12N 1/22
.
Processes using, or culture media containing, cellulose or hydrolysates thereof [2013‑01]
C12N 1/24
.
Processes using, or culture media containing, waste sulfite liquor [2013‑01]
Collapse
C12N 1/26
.
Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using micro-organisms C10G 32/00) [2013‑01]
Collapse
C12N 1/28
. .
aliphatic [2013‑01]
C12N 1/30
. . .
having five or less carbon atoms [2013‑01]
C12N 1/32
.
Processes using, or culture media containing, lower alkanols, i.e. C1 to C6 [2013‑01]
C12N 1/34
.
Processes using foam culture [2013‑01]
C12N 1/36
.
Adaptation or attenuation of cells [2013‑01]
C12N 1/38
.
Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N 1/34 takes precedence) [2013‑01]
Spore forming or isolating processes [2013‑01]
Collapse
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H 4/00) [2013‑01]
NOTE
-
In this group, the following words are used with the meanings indicated: - a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta; - a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm); - a "multipotent" cell is restricted to one lineage; - "progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly forseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.

C12N 5/0006
.
{
Modification of the membrane of cells, e.g. cell decoration
}
[2013‑01]
C12N 5/0012
.
{
Cell encapsulation
}
[2013‑01]
Collapse
C12N 5/0018
.
{
Culture media for cell or tissue culture (media for specific animal cell type C12N 5/06)
}
[2013‑01]
. .
{
Culture media for plant cell or plant tissue culture
}
[2013‑01]
C12N 5/0031
. .
{
Serum-free culture media
}
[2013‑01]
WARNING
-
This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to C12N 5/0037 to C12N 5/0056

C12N 5/0037
. .
{
Serum-free medium, which may still contain naturally-sourced components
}
[2013‑01]
C12N 5/0043
. .
{
Medium free of human- or animal-derived components
}
[2013‑01]
C12N 5/005
. .
{
Protein-free medium
}
[2013‑01]
C12N 5/0056
. .
{
Xeno-free medium
}
[2013‑01]
C12N 5/0062
.
{
General methods for three-dimensional culture
}
[2013‑01]
Collapse
C12N 5/0068
.
{
General culture methods using substrates (for specific animal cell type C12N 5/06)
}
[2013‑01]
C12N 5/0075
. .
{
using microcarriers
}
[2013‑01]
Collapse
C12N 5/0081
.
{
Purging biological preparations of unwanted cells
}
[2013‑01]
C12N 5/0087
. .
{
Purging against subsets of blood cells, e.g. purging alloreactive T cells
}
[2013‑01]
C12N 5/0093
. .
{
Purging against cancer cells
}
[2013‑01]
.
Plant cells or tissues
{
(culture media C12N 5/0025)
}
[2013‑01]
Collapse
C12N 5/06
.
Animal cells or tissues;
{
Human cells or tissues (preservation of living cells or tissues A01N 1/02) ; Not used, see subgroups
}
[2013‑01]
NOTE
-
In this group, the following words are used with the meanings indicated:
- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm,
endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at
least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage.
"Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitely forseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells

C12N 5/0601
. .
{
Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
}
[2013‑01]
Collapse
C12N 5/0602
. .
{
Vertebrate cells
}
[2013‑01]
NOTE
-
Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

Collapse
C12N 5/0603
. . .
{
Embryonic cells (production of embryos, nuclear transfer A01K 67/027) ; Embryoid bodies
}
[2013‑01]
C12N 5/0604
. . . .
{
Whole embryos; Culture medium therefor
}
[2013‑01]
C12N 5/0605
. . . .
{
Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
}
[2013‑01]
. . . .
{
Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N 5/0611 , induced pluripotent stem cells C12N 5/0696)
}
[2013‑01]
. . .
{
Non-embryonic pluripotent stem cells, e.g. MASC
}
(induced pluripotent stem cells C12N 5/0696) [2013‑01]
Collapse
C12N 5/0608
. . .
{
Germ cells (production of embryos, nuclear transfer A01K 67/027) ; Not used, see subgroups
}
[2013‑01]
C12N 5/0609
. . . .
{
Oocytes, oogonia (fertilised oocytes C12N 5/0604)
}
[2013‑01]
C12N 5/061
. . . .
{
Sperm cells, spermatogonia
}
[2013‑01]
C12N 5/0611
. . . .
{
Primordial germ cells, e.g. embryonic germ cells (EG)
}
[2013‑01]
C12N 5/0612
. . . .
{
sorting of gametes, e.g. according to sex or motility
}
[2013‑01]
Collapse
C12N 5/0613
. . .
{
Cells from endocrine organs (pancreas C12N 5/0676 , gonads C12N 5/0681)
}
[2013‑01]
C12N 5/0614
. . . .
{
Adrenal gland
}
[2013‑01]
C12N 5/0615
. . . .
{
Pineal gland
}
[2013‑01]
C12N 5/0616
. . . .
{
Pituitary gland
}
[2013‑01]
C12N 5/0617
. . . .
{
Thyroid and parathyroid glands
}
[2013‑01]
Collapse
C12N 5/0618
. . .
{
Cells of the nervous system
}
[2013‑01]
C12N 5/0619
. . . .
{
Neurons
}
[2013‑01]
C12N 5/062
. . . .
{
Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
}
[2013‑01]
C12N 5/0621
. . . .
{
Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N 5/062)
}
[2013‑01]
C12N 5/0622
. . . .
{
Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
}
[2013‑01]
C12N 5/0623
. . . .
{
Stem cells
}
[2013‑01]
Collapse
C12N 5/0625
. . .
{
Epidermal cells, skin cells; Cells of the oral mucosa
}
[2013‑01]
C12N 5/0626
. . . .
{
Melanocytes
}
[2013‑01]
Collapse
C12N 5/0627
. . . .
{
Hair cells
}
[2013‑01]
C12N 5/0628
. . . . .
{
Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N 5/0666)
}
[2013‑01]
Collapse
C12N 5/0629
. . . .
{
Keratinocytes; Whole skin
}
[2013‑01]
C12N 5/063
. . . . .
{
Kereatinocyte stem cells; Keratinocyte progenitors
}
[2013‑01]
C12N 5/0631
. . . .
{
Mammary cells
}
[2013‑01]
C12N 5/0632
. . . .
{
Cells of the oral mucosa
}
[2013‑01]
C12N 5/0633
. . . .
{
Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
}
[2013‑01]
Collapse
C12N 5/0634
. . .
{
Cells from the blood or the immune system
}
[2013‑01]
NOTE
-
Commited progenitors are classified with their progeny

C12N 5/0635
. . . .
{
B lymphocytes
}
[2013‑01]
Collapse
C12N 5/0636
. . . .
{
T lymphocytes
}
[2013‑01]
C12N 5/0637
. . . . .
{
Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)
}
[2013‑01]
C12N 5/0638
. . . . .
{
Cytotoxic T lymphocytes (CTL), lymphokine activated killer cells (LAK)
}
[2013‑01]
Collapse
C12N 5/0639
. . . .
{
Dendritic cells, e.g. Langherhans cells in the epidermis
}
[2013‑01]
C12N 5/064
. . . . .
{
Immunosuppressive dendritic cells
}
[2013‑01]
C12N 5/0641
. . . .
{
Erythrocytes
}
[2013‑01]
C12N 5/0642
. . . .
{
Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
}
[2013‑01]
C12N 5/0643
. . . .
{
Osteoclasts
}
[2013‑01]
C12N 5/0644
. . . .
{
Platelets; Megakaryocytes
}
[2013‑01]
C12N 5/0645
. . . .
{
Macrophages, e.g. Kuepfer cells in the liver; Monocytes
}
[2013‑01]
C12N 5/0646
. . . .
{
Natural killers cells (NK), NKT cells
}
[2013‑01]
. . . .
{
Haematopoietic stem cells; Uncommited or multipotent progenitors
}
[2013‑01]
C12N 5/0648
. . . .
{
Splenocytes
}
[2013‑01]
C12N 5/065
. . . .
{
Thymocytes
}
[2013‑01]
C12N 5/0651
. . . .
{
Lymph nodes
}
[2013‑01]
Collapse
C12N 5/0652
. . .
{
Cells of skeletal and connective tissues; Mesenchyme
}
[2013‑01]
C12N 5/0653
. . . .
{
Adipocytes; Adipose tissue
}
[2013‑01]
C12N 5/0654
. . . .
{
Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
}
[2013‑01]
C12N 5/0655
. . . .
{
Chondrocytes; Cartilage
}
[2013‑01]
C12N 5/0656
. . . .
{
Adult fibroblasts
}
[2013‑01]
C12N 5/0657
. . . .
{
Cardiomyocytes; Heart cells
}
[2013‑01]
Collapse
C12N 5/0658
. . . .
{
Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
}
[2013‑01]
C12N 5/0659
. . . . .
{
Satellite cells
}
[2013‑01]
C12N 5/066
. . . .
{
Tenocytes; Tendons, Ligaments
}
[2013‑01]
C12N 5/0661
. . . .
{
Smooth muscle cells
}
[2013‑01]
Collapse
C12N 5/0662
. . . .
{
Stem cells
}
[2013‑01]
C12N 5/0663
. . . . .
{
Bone marrow mesenchymal stem cells (BM-MSC)
}
[2013‑01]
C12N 5/0664
. . . . .
{
Dental pulp stem cells, Dental follicle stem cells
}
[2013‑01]
C12N 5/0665
. . . . .
{
Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
}
[2013‑01]
C12N 5/0666
. . . . .
{
Mesenchymal stem cells from hair follicles
}
[2013‑01]
C12N 5/0667
. . . . .
{
Adipose-derived stem cells (ADSC); Adipose stromal stem cells
}
[2013‑01]
C12N 5/0668
. . . . .
{
Mesenchymal stem cells from other natural sources
}
[2013‑01]
C12N 5/0669
. . . .
{
Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647 , C12N 5/0663)
}
[2013‑01]
Collapse
C12N 5/067
. . .
{
Hepatocytes
}
[2013‑01]
C12N 5/0671
. . . .
{
Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
}
[2013‑01]
C12N 5/0672
. . . .
{
Stem cells; Progenitor cells; Precursor cells; Oval cells
}
[2013‑01]
Collapse
C12N 5/0673
. . .
{
Cells from bone marrow stroma
}
[2013‑01]
C12N 5/0675
. . . .
{
Mesenchymal stem cells
}
[2013‑01]
Collapse
C12N 5/0676
. . .
{
Pancreatic cells
}
[2013‑01]
C12N 5/0677
. . . .
{
Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
}
[2013‑01]
C12N 5/0678
. . . .
{
Stem cells; Progenitor cells; Precursor cells
}
[2013‑01]
Collapse
C12N 5/0679
. . .
{
Cells of the gastro-intestinal tract
}
[2013‑01]
C12N 5/068
. . . .
{
Stem cells; Progenitors
}
[2013‑01]
Collapse
C12N 5/0681
. . .
{
Cells of the genital tract; Non-germinal cells from gonads; Not used, see subgroups
}
[2013‑01]
C12N 5/0682
. . . .
{
Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0609)
}
[2013‑01]
C12N 5/0683
. . . .
{
Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/061)
}
[2013‑01]
Collapse
C12N 5/0684
. . .
{
Cells of the urinary tract or kidneys
}
[2013‑01]
C12N 5/0685
. . . .
{
Bladder epithelial cells
}
[2013‑01]
C12N 5/0686
. . . .
{
Kidney cells
}
[2013‑01]
C12N 5/0687
. . . .
{
Renal stem cells; Renal progenitors
}
[2013‑01]
Collapse
C12N 5/0688
. . .
{
Cells from the lungs or the respiratory tract
}
[2013‑01]
C12N 5/0689
. . . .
{
Stem cells; Progenitors
}
[2013‑01]
Collapse
C12N 5/069
. . .
{
Vascular Endothelial cells
}
[2013‑01]
C12N 5/0691
. . . .
{
Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
}
[2013‑01]
C12N 5/0692
. . . .
{
Stem cells; Progenitor cells; Precursor cells
}
[2013‑01]
Collapse
C12N 5/0693
. . .
{
Tumour cells; Cancer cells
}
[2013‑01]
C12N 5/0694
. . . .
{
Cells of blood, e.g. leukemia cells, myeloma cells
}
[2013‑01]
C12N 5/0695
. . . .
{
Stem cells; Progenitor cells; Precursor cells
}
[2013‑01]
C12N 5/0696
. . .
{
Artificially induced pluripotent stem cells, e.g. iPS
}
[2013‑01]
Collapse
C12N 5/0697
. .
{
Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N 5/0691)
}
[2013‑01]
C12N 5/0698
. . .
{
Skin equivalents
}
[2013‑01]
Collapse
C12N 5/10
.
Cells modified by introduction of foreign genetic material
{
Not used, see subgroups
}
[2013‑01]
Collapse
C12N 5/12
. .
Fused cells, e.g. hybridomas [2013‑01]
. . .
Plant cells [2013‑01]
Collapse
C12N 5/16
. . .
Animal cells [2013‑01]
C12N 5/163
. . . .
{
one of the fusion partners being a B or a T lymphocyte
}
[2013‑01]
C12N 5/166
. . . .
{
resulting from interspecies fusion
}
[2013‑01]
Collapse
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody composition, e.g. virus vaccines, A61K 39/00) [2013‑01]
WARNING
-
From March 15, 2012 groups C12N 7/02 - C12N 7/08 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00-C12N 2795/00.

Collapse
C12N 7/02
.
Recovery or purification [2013‑01]
C12N 7/025
. .
{
Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
}
[2013‑01]
Collapse
C12N 7/04
.
Inactivation or attenuation; Producing viral sub-units [2013‑01]
C12N 7/045
. .
{
Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
}
[2013‑01]
C12N 7/06
. .
{
Inactivation or attenuation
}
by chemical treatment [2013‑01]
C12N 7/08
. .
{
Inactivation or attenuation
}
by serial passage of virus [2013‑01]
Collapse
Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K 8/66 , A61Q 11/00 ; medicinal preparations containing enzymes or pro-enzymes A61K 38/43 ; enzyme containing detergent compositions C11D ;
{
enzymes with nucleic acid structure, e.g. ribozymes, C12N 15/113
}
)
; Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C 1/00) [2013‑01]
NOTE
-
Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.

C12N 9/0002
.
{
Antibodies with enzymatic activity; e.g. abzymes
}
[2013‑01]
Collapse
C12N 9/0004
.
{
Oxidoreductases (1.)
}
[2013‑01]
C12N 9/0006
. .
{
acting on CH-OH groups as donors (1.1)
}
[2013‑01]
C12N 9/0008
. .
{
acting on the aldehyde or oxo group of donors (1.2)
}
[2013‑01]
C12N 9/001
. .
{
acting on the CH-CH group of donors (1.3)
}
[2013‑01]
Collapse
C12N 9/0012
. .
{
acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
}
[2013‑01]
Collapse
C12N 9/0014
. . .
{
acting on the CH-NH2 group of donors (1.4)
}
[2013‑01]
Collapse
C12N 9/0016
. . . .
{
with NAD or NADP as acceptor (1.4.1)
}
[2013‑01]
C12N 9/0018
. . . . .
{
Phenylalanine dehydrogenase (1.4.1.20)
}
[2013‑01]
C12N 9/002
. . . .
{
with a cytochrome as acceptor (1.4.2)
}
[2013‑01]
Collapse
C12N 9/0022
. . . .
{
with oxygen as acceptor (1.4.3)
}
[2013‑01]
C12N 9/0024
. . . . .
{
D-Amino acid oxidase (1.4.3.3)
}
[2013‑01]
Collapse
C12N 9/0026
. . .
{
acting on CH-NH groups of donors (1.5)
}
[2013‑01]
Collapse
C12N 9/0028
. . . .
{
with NAD or NADP as acceptor (1.5.1)
}
[2013‑01]
C12N 9/003
. . . . .
{
Dihydrofolate reductase (DHFR) (1.5.1.3)
}
[2013‑01]
Collapse
C12N 9/0032
. . . .
{
with oxygen as acceptor (1.5.3)
}
[2013‑01]
C12N 9/0034
. . . . .
{
Sarcosine oxidase (1.5.3.1)
}
[2013‑01]
Collapse
C12N 9/0036
. . .
{
acting on NADH or NADPH (1.6)
}
[2013‑01]
Collapse
C12N 9/0038
. . . .
{
with a heme protein as acceptor (1.6.2)
}
[2013‑01]
C12N 9/004
. . . . .
{
Cytochrome-b5 reductase (1.6.2.2)
}
[2013‑01]
C12N 9/0042
. . . . .
{
NADPH-cytochrome P450 reductase (1.6.2.4)
}
[2013‑01]
Collapse
C12N 9/0044
. . .
{
acting on other nitrogen compounds as donors (1.7)
}
[2013‑01]
Collapse
C12N 9/0046
. . . .
{
with oxygen as acceptor (1.7.3)
}
[2013‑01]
C12N 9/0048
. . . . .
{
Uricase (1.7.3.3)
}
[2013‑01]
C12N 9/0051
. .
{
acting on a sulfur group of donors (1.8)
}
[2013‑01]
C12N 9/0053
. .
{
acting on a heme group of donors (1.9)
}
[2013‑01]
Collapse
C12N 9/0055
. .
{
acting on diphenols and related substances as donors (1.10)
}
[2013‑01]
Collapse
C12N 9/0057
. . .
{
with oxygen as acceptor (1.10.3)
}
[2013‑01]
C12N 9/0059
. . . .
{
Catechol oxidase (1.10.3.1), i.e. tyrosinase
}
[2013‑01]
C12N 9/0061
. . . .
{
Laccase (1.10.3.2)
}
[2013‑01]
C12N 9/0063
. . . .
{
Ascorbate oxidase (1.10.3.3)
}
[2013‑01]
C12N 9/0065
. .
{
acting on hydrogen peroxide as acceptor (1.11)
}
[2013‑01]
C12N 9/0067
. .
{
acting on hydrogen as donor (1.12)
}
[2013‑01]
C12N 9/0069
. .
{
acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
}
[2013‑01]
Collapse
C12N 9/0071
. .
{
acting on paired donors with incorporation of molecular oxygen (1.14)
}
[2013‑01]
Collapse
C12N 9/0073
. . .
{
with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
}
[2013‑01]
C12N 9/0075
. . . .
{
Nitric-oxide synthase (1.14.13.39)
}
[2013‑01]
Collapse
C12N 9/0077
. . .
{
with a reduced iron-sulfur protein as one donor (1.14.15)
}
[2013‑01]
C12N 9/0079
. . . .
{
Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)
}
[2013‑01]
C12N 9/0081
. . . .
{
Cholesterol monooxygenase (cytochrome P 450scc)(1.14.15.6)
}
[2013‑01]
Collapse
C12N 9/0083
. . .
{
Miscellaneous (1.14.99)
}
[2013‑01]
C12N 9/0085
. . . .
{
Steroid 17 alpha-monooxygenase (1.14.99.9)
}
[2013‑01]
C12N 9/0087
. . . .
{
Steroid 21-monooxygenase (1.14.99.10)
}
[2013‑01]
C12N 9/0089
. .
{
acting on superoxide as acceptor (1.15)
}
[2013‑01]
C12N 9/0091
. .
{
oxidizing metal ions (1.16)
}
[2013‑01]
C12N 9/0093
. .
{
acting on CH or CH2 groups (1.17)
}
[2013‑01]
C12N 9/0095
. .
{
acting on iron-sulfur proteins as donor (1.18)
}
[2013‑01]
C12N 9/0097
. .
{
acting on reduced flavodoxin as donor (1.19)
}
[2013‑01]
Collapse
C12N 9/10
.
Transferases (2.) (ribonucleases C12N 9/22) [2013‑01]
Collapse
C12N 9/1003
. .
{
transferring one-carbon groups (2.1)
}
[2013‑01]
Collapse
C12N 9/1007
. . .
{
Methyltransferases (general) (2.1.1.)
}
[2013‑01]
C12N 9/1011
. . . .
{
Catechol O-methyltransferase (2.1.1.6)
}
[2013‑01]
C12N 9/1014
. . .
{
Hydroxymethyl-, formyl-transferases (2.1.2)
}
[2013‑01]
C12N 9/1018
. . .
{
Carboxy- and carbamoyl transferases (2.1.3)
}
[2013‑01]
C12N 9/1022
. .
{
transferring aldehyde or ketonic groups (2.2)
}
[2013‑01]
Collapse
C12N 9/1025
. .
{
Acyltransferases (2.3)
}
[2013‑01]
Collapse
C12N 9/1029
. . .
{
transferring groups other than amino-acyl groups (2.3.1)
}
[2013‑01]
C12N 9/1033
. . . .
{
Chloramphenicol O-acetyltransferase (2.3.1.28)
}
[2013‑01]
C12N 9/1037
. . . .
{
Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase
}
[2013‑01]
Collapse
C12N 9/104
. . .
{
Aminoacyltransferases (2.3.2)
}
[2013‑01]
C12N 9/1044
. . . .
{
Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
}
[2013‑01]
Collapse
C12N 9/1048
. .
{
Glycosyltransferases (2.4)
}
[2013‑01]
Collapse
C12N 9/1051
. . .
{
Hexosyltransferases (2.4.1)
}
[2013‑01]
C12N 9/1055
. . . .
{
Levansucrase (2.4.1.10)
}
[2013‑01]
C12N 9/1059
. . . .
{
Cellulose synthases (2.4.1.12; 2.4.1.29)
}
[2013‑01]
C12N 9/1062
. . . .
{
Sucrose synthase (2.4.1.13)
}
[2013‑01]
C12N 9/1066
. . . .
{
Sucrose phosphate synthase (2.4.1.14)
}
[2013‑01]
C12N 9/107
. . . .
{
1,4-Alpha-glucan branching enzyme (2.4.1.18)
}
[2013‑01]
C12N 9/1074
. . . .
{
Cyclomaltodextrin glucanotransferase (2.4.1.19)
}
[2013‑01]
C12N 9/1077
. . .
{
Pentosyltransferases (2.4.2)
}
[2013‑01]
C12N 9/1081
. . .
{
transferring other glycosyl groups (2.4.99)
}
[2013‑01]
Collapse
C12N 9/1085
. .
{
transferring alkyl or aryl groups other than methyl groups (2.5)
}
[2013‑01]
C12N 9/1088
. . .
{
Glutathione transferase (2.5.1.18)
}
[2013‑01]
C12N 9/1092
. . .
{
3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase
}
[2013‑01]
C12N 9/1096
. .
{
transferring nitrogenous groups (2.6)
}
[2013‑01]
Collapse
C12N 9/12
. .
transferring phosphorus containing groups, e.g. kinases (2.7) [2013‑01]
Collapse
C12N 9/1205
. . .
{
Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
}
[2013‑01]
C12N 9/1211
. . . .
{
Thymidine kinase (2.7.1.21)
}
[2013‑01]
C12N 9/1217
. . .
{
Phosphotransferases with a carboxyl group as acceptor (2.7.2)
}
[2013‑01]
C12N 9/1223
. . .
{
Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
}
[2013‑01]
C12N 9/1229
. . .
{
Phosphotransferases with a phosphate group as acceptor (2.7.4)
}
[2013‑01]
C12N 9/1235
. . .
{
Diphosphotransferases (2.7.6)
}
[2013‑01]
Collapse
C12N 9/1241
. . .
{
Nucleotidyltransferases (2.7.7)
}
[2013‑01]
C12N 9/1247
. . . .
{
DNA-directed RNA polymerase (2.7.7.6)
}
[2013‑01]
C12N 9/1252
. . . .
{
DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
}
[2013‑01]
C12N 9/1258
. . . .
{
Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase
}
[2013‑01]
C12N 9/1264
. . . .
{
DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
}
[2013‑01]
C12N 9/127
. . . .
{
RNA-directed RNA polymerase (2.7.7.48), i.e RNA replicase
}
[2013‑01]
C12N 9/1276
. . . .
{
RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
}
[2013‑01]
C12N 9/1282
. . . .
{
RNA uridylyltransferase (2.7.7.52)
}
[2013‑01]
C12N 9/1288
. . .
{
Transferases for other substituted phosphate groups (2.7.8)
}
[2013‑01]
C12N 9/1294
. . .
{
Phosphotransferases with paired acceptors (2.7.9)
}
[2013‑01]
C12N 9/13
. .
{
transferring sulfur containing groups (2.8)
}
[2013‑01]
Collapse
C12N 9/14
.
Hydrolases (3) [2013‑01]
Collapse
C12N 9/16
. .
acting on ester bonds (3.1) [2013‑01]
Collapse
C12N 9/18
. . .
Carboxylic ester hydrolases
{
(3.1.1)
}
[2013‑01]
C12N 9/20
. . . .
Triglyceride splitting, e.g. by means of lipase [2013‑01]
C12N 9/22
. . .
Ribonucleases
{
RNAses, DNAses (catalytic nucleic acids C12N 15/113)
}
[2013‑01]
Collapse
C12N 9/24
. .
acting on glycosyl compounds (3.2) [2013‑01]
Collapse
C12N 9/2402
. . .
{
hydrolysing O- and S- glycosyl compounds (3.2.1)
}
[2013‑01]
Collapse
C12N 9/2405
. . . .
{
Glucanases
}
[2013‑01]
Collapse
C12N 9/2408
. . . . .
{
acting on alpha -1,4-glucosidic bonds
}
[2013‑01]
Collapse
C12N 9/2411
. . . . . .
{
Amylases
}
[2013‑01]
Collapse
C12N 9/2414
. . . . . . .
{
Alpha-amylase (3.2.1.1.)
}
[2013‑01]
Collapse
C12N 9/2417
. . . . . . . .
{
from microbiological source
}
[2013‑01]
C12N 9/242
. . . . . . . . .
{
Fungal source
}
[2013‑01]
C12N 9/2422
. . . . . . . .
{
from plant source
}
[2013‑01]
C12N 9/2425
. . . . . . .
{
Beta-amylase (3.2.1.2)
}
[2013‑01]
C12N 9/2428
. . . . . . .
{
Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
}
[2013‑01]
C12N 9/2431
. . . . . .
{
Beta-fructofuranosidase (3.2.1.26), i.e. invertase
}
[2013‑01]
Collapse
C12N 9/2434
. . . . .
{
acting on beta-1,4-glucosidic bonds
}
[2013‑01]
C12N 9/2437
. . . . . .
{
Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
}
[2013‑01]
C12N 9/244
. . . . . .
{
Endo-1,3(4)-beta-glucanase (3.2.1.6)
}
[2013‑01]
C12N 9/2442
. . . . . .
{
Chitinase (3.2.1.14)
}
[2013‑01]
C12N 9/2445
. . . . . .
{
Beta-glucosidase (3.2.1.21)
}
[2013‑01]
C12N 9/2448
. . . . . .
{
Licheninase (3.2.1.73)
}
[2013‑01]
Collapse
C12N 9/2451
. . . . .
{
acting on alpha-1,6-glucosidic bonds
}
[2013‑01]
C12N 9/2454
. . . . . .
{
Dextranase (3.2.1.11)
}
[2013‑01]
C12N 9/2457
. . . . . .
{
Pullulanase (3.2.1.41)
}
[2013‑01]
C12N 9/246
. . . . . .
{
Isoamylase (3.2.1.68)
}
[2013‑01]
C12N 9/2462
. . . .
{
Lysozyme (3.2.1.17)
}
[2013‑01]
C12N 9/2465
. . . .
{
acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
}
[2013‑01]
Collapse
C12N 9/2468
. . . .
{
acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
}
[2013‑01]
C12N 9/2471
. . . . .
{
Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
}
[2013‑01]
C12N 9/2474
. . . .
{
Hyaluronoglucosaminidase (3.2.1.35), i.e hyaluronidase
}
[2013‑01]
Collapse
C12N 9/2477
. . . .
{
Hemicellulases not provided in a preceding group
}
[2013‑01]
Collapse
C12N 9/248
. . . . .
{
Xylanases
}
[2013‑01]
C12N 9/2482
. . . . . .
{
Endo-1,4-beta-xylanase (3.2.1.8)
}
[2013‑01]
C12N 9/2485
. . . . . .
{
Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase
}
[2013‑01]
Collapse
C12N 9/2488
. . . . .
{
Mannanases
}
[2013‑01]
C12N 9/2491
. . . . . .
{
Beta-mannosidase (3.2.1.25), i.e. mannanase
}
[2013‑01]
C12N 9/2494
. . . . . .
{
Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase
}
[2013‑01]
C12N 9/2497
. . .
{
hydrolysing N- glycosyl compounds (3.2.2)
}
[2013‑01]
Collapse
C12N 9/48
. .
acting on peptide bonds (3.4) [2013‑01]
C12N 9/485
. . .
{
Exopeptidases (3.4.11-3.4.19)
}
[2013‑01]
Collapse
C12N 9/50
. . .
Proteinases
{
Endopeptidases (3.4.21-3.4.25)
}
[2013‑01]
Collapse
C12N 9/503
. . . .
{
derived from viruses
}
[2013‑01]
C12N 9/506
. . . . .
{
derived from RNA viruses
}
[2013‑01]
Collapse
C12N 9/52
. . . .
derived from bacteria [2013‑01]
C12N 9/54
. . . . .
bacteria being Bacillus [2013‑01]
Collapse
C12N 9/58
. . . .
derived from fungi [2013‑01]
C12N 9/60
. . . . .
from yeast [2013‑01]
C12N 9/62
. . . . .
from Aspergillus [2013‑01]
C12N 9/63
. . . .
{
derived from plants
}
[2013‑01]
Collapse
C12N 9/64
. . . .
derived from animal tissue [2013‑01]
Collapse
C12N 9/6402
. . . . .
{
from non-mammals
}
[2013‑01]
Collapse
C12N 9/6405
. . . . . .
{
not being snakes
}
[2013‑01]
C12N 9/6408
. . . . . . .
{
Serine endopeptidases (3.4.21)
}
[2013‑01]
C12N 9/641
. . . . . . .
{
Cysteine endopeptidases (3.4.22)
}
[2013‑01]
C12N 9/6413
. . . . . . .
{
Aspartic endopeptidases (3.4.23)
}
[2013‑01]
C12N 9/6416
. . . . . . .
{
Metalloendopeptidases (3.4.24)
}
[2013‑01]
C12N 9/6418
. . . . . .
{
from snakes
}
[2013‑01]
Collapse
C12N 9/6421
. . . . .
{
from mammals
}
[2013‑01]
Collapse
C12N 9/6424
. . . . . .
{
Serine endopeptidases (3.4.21)
}
[2013‑01]
C12N 9/6427
. . . . . . .
{
Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
}
[2013‑01]
C12N 9/6429
. . . . . . .
{
Thrombin (3.4.21.5)
}
[2013‑01]
C12N 9/6432
. . . . . . .
{
Coagulation factor Xa (3.4.21.6)
}
[2013‑01]
C12N 9/6435
. . . . . . .
{
Plasmin (3.4.21.7), i.e. fibrinolysin
}
[2013‑01]
C12N 9/6437
. . . . . . .
{
Coagulation factor VIIa (3.4.21.21)
}
[2013‑01]
C12N 9/644
. . . . . . .
{
Coagulation factor IXa (3.4.21.22)
}
[2013‑01]
C12N 9/6443
. . . . . . .
{
Coagulation factor XIa (3.4.21.27)
}
[2013‑01]
C12N 9/6445
. . . . . . .
{
Kallikreins (3.4.21.34; 3.4.21.35)
}
[2013‑01]
C12N 9/6448
. . . . . . .
{
Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)
}
[2013‑01]
C12N 9/6451
. . . . . . .
{
Coagulation factor XIIa (3.4.21.38)
}
[2013‑01]
C12N 9/6454
. . . . . . .
{
Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
}
[2013‑01]
Collapse
C12N 9/6456
. . . . . . .
{
Plasminogen activators
}
[2013‑01]
C12N 9/6459
. . . . . . . .
{
t-plasminogen activator (3.4.21.68), i.e. tPA
}
[2013‑01]
C12N 9/6462
. . . . . . . .
{
u-Plasminogen activator (3.4.21.73), i.e. urokinase
}
[2013‑01]
C12N 9/6464
. . . . . . .
{
Protein C (3.4.21.69)
}
[2013‑01]
C12N 9/6467
. . . . . . .
{
Granzymes, e.g granzyme A (3.4.21.78); granzyme B (3.4.21.79)
}
[2013‑01]
C12N 9/647
. . . . . . .
{
Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
}
[2013‑01]
Collapse
C12N 9/6472
. . . . . .
{
Cysteine endopeptidases (3.4.22)
}
[2013‑01]
C12N 9/6475
. . . . . . .
{
Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
}
[2013‑01]
Collapse
C12N 9/6478
. . . . . .
{
Aspartic endopeptidases (3.4.23)
}
[2013‑01]
C12N 9/6481
. . . . . . .
{
Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
}
[2013‑01]
C12N 9/6483
. . . . . . .
{
Chymosin (3.4.23.4), i.e. rennin
}
[2013‑01]
C12N 9/6486
. . . . . . .
{
Renin (3.4.23.15)
}
[2013‑01]
Collapse
C12N 9/6489
. . . . . .
{
Metalloendopeptidases (3.4.24)
}
[2013‑01]
C12N 9/6491
. . . . . . .
{
Matrix metalloproteases (MMP's), e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
}
[2013‑01]
C12N 9/6494
. . . . . . .
{
Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11
}
[2013‑01]
C12N 9/6497
. . . . . . .
{
Endothelin-converting enzyme (3.4.24.71)
}
[2013‑01]
Collapse
C12N 9/78
. .
acting on carbon to nitrogen bonds other than peptide bonds (3.5) [2013‑01]
Collapse
C12N 9/80
. . .
acting on amide bonds in linear amides
{
(3.5.1)
}
[2013‑01]
C12N 9/82
. . . .
Asparaginase
{
(3.5.1.1)
}
[2013‑01]
C12N 9/84
. . . .
Penicillin amidase
{
(3.5.1.11)
}
[2013‑01]
C12N 9/86
. . .
acting on amide bonds in cyclic amides, e.g. penicillinase
{
(3.5.2)
}
[2013‑01]
C12N 9/88
.
Lyases (4.) [2013‑01]
Collapse
C12N 9/90
.
Isomerases (5.) [2013‑01]
C12N 9/92
. .
Glucose isomerase
{
(5.3.1.5; 5.3.1.9; 5.3.1.18)
}
[2013‑01]
C12N 9/93
.
{
Ligases (6)
}
[2013‑01]
C12N 9/94
.
Pancreatin [2013‑01]
.
Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates [2013‑01]
.
Preparation of granular or free-flowing enzyme compositions (C12N 9/96 takes precedence) [2013‑01]
C12N 9/99
.
Enzyme inactivation by chemical treatment [2013‑01]
Collapse
Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof [2013‑01]
Collapse
C12N 11/02
.
Enzymes or microbial cells being immobilised on or in an organic carrier [2013‑01]
C12N 11/04
. .
entrapped within the carrier, e.g. gel, hollow fibre [2013‑01]
C12N 11/06
. .
attached to the carrier via a bridging agent [2013‑01]
C12N 11/08
. .
carrier being a synthetic polymer [2013‑01]
Collapse
C12N 11/10
. .
carrier being a carbohydrate [2013‑01]
C12N 11/12
. . .
Cellulose or derivative thereof [2013‑01]
C12N 11/14
.
Enzymes or microbial cells being immobilised on or in an inorganic carrier [2013‑01]
C12N 11/16
.
Enzymes or microbial cells being immobilised on or in a biological cell [2013‑01]
C12N 11/18
.
Multi-enzyme systems [2013‑01]
Treatment of micro-organisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves [2013‑01]
Collapse
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered micro-organisms, per se C12N 1/00 , C12N 5/00 , C12N 7/00 ; new plants per se A01H ; plant reproduction by tissue culture techniques A01H 4/00 ; new animals per se A01K 67/00 ; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K 48/00) [2013‑01]
.
Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor [2013‑01]
Collapse
.
Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
{
(monoclonal antibodies C07K 16/00 ; apparatus for cell fusion C12M)
}
[2013‑01]
C12N 15/03
. .
Bacteria [2013‑01]
C12N 15/04
. .
Fungi [2013‑01]
Collapse
.
Recombinant DNA-technology [2013‑01]
Collapse
. .
Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H 21/00 ; preparation of non-structural polynucleotides from micro-organisms or with enzymes C12P 19/34) [2013‑01]
NOTE
-
After the symbol C12N 15/10 to C12N 15/1096, and separated therefrom by a + sign, it is desirable to add the indexing codes selected from groups C12Q 2500/00 to C12Q599/00 , relating to relevant technical features of the invention. When more than one indexing code is selected, the different codes are separated by a + sign. Example : C12N 15/1037 + C12Q537/125 + C12Q521/537

Collapse
. . .
{
Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
}
[2013‑01]
Collapse
. . . .
{
by means of a solid support carrier, e.g. particles, polymers
}
[2013‑01]
. . . . .
{
by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
}
[2013‑01]
. . . . .
{
by using magnetic beads
}
[2013‑01]
. . . .
{
by filtration, e.g. using filters, frits, membranes
}
[2013‑01]
Collapse
. . .
{
Mutagenizing nucleic acids
}
[2013‑01]
. . . .
{
In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair
}
[2013‑01]
. . . .
{
by DNA shuffling, e.g. RSR, STEP, RPR
}
[2013‑01]
. . . .
{
mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
}
[2013‑01]
Collapse
. . .
{
Isolating an individual clone by screening libraries
}
[2013‑01]
. . . .
{
Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
}
[2013‑01]
. . . .
{
Ribosome/Polysome display, e.g. SPERT, ARM
}
[2013‑01]
. . . .
{
Preparation or screening of libraries displayed on scaffold proteins
}
s [2013‑01]
. . . .
{
SELEX
}
[2013‑01]
. . . .
{
Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
}
[2013‑01]
. . . .
{
Protein x Protein interaction, e.g. two hybrid selection
}
[2013‑01]
. . . .
{
Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
}
[2013‑01]
. . . .
{
mRNA-Display, e.g. polypeptide and encoding template are connected covalently
}
[2013‑01]
. . . .
{
Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
}
[2013‑01]
. . . .
{
Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis (NRPS), DNA/RNA-polymerase mediated polypeptide synthesis
}
[2013‑01]
. . . .
{
Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
}
[2013‑01]
. . . .
{
by coupling phenotype to genotype, not provided for in other groups of this subclass
}
[2013‑01]
. . . .
{
Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N 15/1086)
}
[2013‑01]
. . . .
{
Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
}
[2013‑01]
. . . .
{
Preparation or screening of expression libraries, e.g. reporter assays
}
[2013‑01]
. . . .
{
Design, preparation, screening or analysis of libraries using computer algorithms
}
[2013‑01]
. . . .
{
General methods of preparing gene libraries, not provided for in other subgroups
}
[2013‑01]
. . .
{
cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
}
[2013‑01]
Collapse
. .
DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H 21/00);
{
Non-coding nucleic acids having a biological activity
}
[2013‑01]
NOTE
-
Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups C12N 15/11 to C12N 15/117 cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The C12N2300/00 ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group C12N 15/111


. . .
{
General methods applicable to biologically active non-coding nucleic acids
}
[2013‑01]
Collapse
. . .
Non-coding nucleic acids modulating the expression of genes, e.g.antisense oligonucleotides;
{
Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N 15/8218)
}
[2013‑01]
Collapse
C12N 15/1131
. . . .
{
against viruses
}
[2013‑01]
C12N 15/1132
. . . . .
{
against retroviridae, e.g. HIV
}
[2013‑01]
C12N 15/1133
. . . . .
{
against herpetoviridae, e.g. HSV
}
[2013‑01]
. . . .
{
against oncogenes or tumor suppressor genes
}
[2013‑01]
C12N 15/1136
. . . .
{
against growth factors, growth regulators, cytokines, lymphokines or hormones
}
[2013‑01]
. . . .
{
against enzymes (viral enzymes C12N 15/1131 ; receptors C12N 15/1138)
}
[2013‑01]
. . . .
{
against receptors or cell surface proteins
}
[2013‑01]
. . .
Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith;
{
Nucleic acids binding to non-nucleic acids, e.g. aptamers
}
[2013‑01]
NOTE
-
Aptamers fused to compounds which are already classified in groups C12N 15/11 to C12N 15/117 , are classified with the corresponding compound

. . .
Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs [2013‑01]
. . .
Genes encoding for enzymes or proenzymes [2013‑01]
NOTE
-
In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.

Collapse
. . .
DNA sequences coding for fusion proteins [2013‑01]
NOTE
-
In this group, the following term is used with the meaning indicated:
- "fusion" means the fusion of two different proteins.

. . . .
{
containing a sequence coding for a signal sequence
}
[2013‑01]
Collapse
. .
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression [2013‑01]
. . .
{
Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
}
[2013‑01]
. . .
General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host [2013‑01]
. . .
using markers (enzymes used as markers C12N 15/52) [2013‑01]
. . .
General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease [2013‑01]
NOTE
-
In this group, the following expression is used with the meaning indicated:
- "non-functional linkers" means DNA sequences which are used to link DNA sequences
and which have no known function of structural gene or regulating function.

Collapse
. . .
General methods for enhancing the expression [2013‑01]
. . . .
Stabilisation of the vector [2013‑01]
. . . .
Increasing the copy number of the vector [2013‑01]
Collapse
. . .
Vectors or expression systems specially adapted for E. coli [2013‑01]
NOTE
-
This group covers the use of E. coli as host.

Shuttle vectors also replicating in E. coli are classified according to the other host.

. . . .
Expression systems using regulatory sequences derived from the trp-operon [2013‑01]
. . . .
Expression systems using regulatory sequences derived from the lac-operon [2013‑01]
. . . .
Expression systems using phage (lambda) regulatory sequences [2013‑01]
Collapse
. . .
Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora [2013‑01]
NOTE
-
This group covers the use of prokaryotes as hosts.

. . . .
{
for Agrobacterium; Rhizobium; Bradyrhizobium
}
[2013‑01]
. . . .
{
for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
}
[2013‑01]
. . . .
for Bacillus [2013‑01]
. . . .
for Actinomyces; for Streptomyces [2013‑01]
. . . .
for Corynebacterium; for Brevibacterium [2013‑01]
. . . .
for Pseudomonas [2013‑01]
Collapse
. . .
Vectors or expression systems specially adapted for eukaryotic hosts [2013‑01]
NOTE
-
This group covers the use of eukaryotes as hosts.

Collapse
. . . .
for fungi [2013‑01]
Collapse
. . . . .
for yeasts [2013‑01]
. . . . . .
{
for yeasts other than Saccharomyces
}
[2013‑01]
Collapse
. . . .
for plant cells,
{
e.g. plant artificial chromosomes (PACs)
}
[2013‑01]
NOTE
-
Documents are being continuously reclassified into this new classification scheme. See Warning notes below

Collapse
C12N 15/8201
. . . . .
{
Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
}
[2013‑01]
Collapse
C12N 15/8202
. . . . . .
{
by biological means, e.g. cell mediated or natural vector
}
[2013‑01]
C12N 15/8203
. . . . . . .
{
Virus mediated transformation
}
[2013‑01]
C12N 15/8205
. . . . . . .
{
Agrobacterium mediated transformation
}
[2013‑01]
Collapse
C12N 15/8206
. . . . . .
{
by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
}
[2013‑01]
C12N 15/8207
. . . . . . .
{
by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers
}
[2013‑01]
Collapse
C12N 15/8209
. . . . . .
{
Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers
}
[2013‑01]
NOTE
-
Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in C12N 15/8209

Collapse
C12N 15/821
. . . . . . .
{
Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8209

C12N 15/8212
. . . . . . . .
{
Colour markers, e.g. beta-glucoronidase (GUS), green fluorescent protein (GFP), carotenoid
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8209

. . . . . .
{
Targeted insertion of genes into the plant genome by homologous recombination
}
[2013‑01]
. . . . . .
{
Plastid transformation
}
[2013‑01]
Collapse
C12N 15/8216
. . . . .
{
Methods for controlling, regulating or enhancing expression of transgenes in plant cells
}
[2013‑01]
. . . . . .
{
Gene switch
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8216

C12N 15/8218
. . . . . .
{
Antisense, co-suppression, viral induced gene silencing (VIGS), post-transcriptional induced gene silencing (PTGS)
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8216

C12N 15/822
. . . . . .
{
Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8216

. . . . . .
{
Transit peptides
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8216

Collapse
C12N 15/8222
. . . . . .
{
Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation
}
[2013‑01]
Collapse
C12N 15/8223
. . . . . . .
{
Vegetative tissue-specific promoters
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8222

C12N 15/8225
. . . . . . . .
{
Leaf-specific, e.g. including petioles, stomata
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8222

C12N 15/8226
. . . . . . . .
{
Stem-specific, e.g. including tubers, beets
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8222

C12N 15/8227
. . . . . . . .
{
Root-specific
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8222

C12N 15/8229
. . . . . . . .
{
Meristem-specific, e.g. nodal, apical
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8222

Collapse
C12N 15/823
. . . . . . .
{
Reproductive tissue-specific promoters
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8222

C12N 15/8231
. . . . . . . .
{
Male-specific, e.g. anther, tapetum, pollen
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8222

C12N 15/8233
. . . . . . . .
{
Female-specific, e.g. pistil, ovule
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8222

C12N 15/8234
. . . . . . . .
{
Seed-specific, e.g. embryo, endosperm
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8222

C12N 15/8235
. . . . . . . .
{
Fruit-specific
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8222

Collapse
C12N 15/8237
. . . . . .
{
Externally regulated expression systems
}
[2013‑01]
C12N 15/8238
. . . . . . .
{
chemically inducible, e.g. tetracycline
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8237

C12N 15/8239
. . . . . . .
{
pathogen inducible
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8237

Collapse
C12N 15/8241
. . . . .
{
Phenotypically and genetically modified plants via recombinant DNA technology
}
[2013‑01]
Collapse
. . . . . .
{
with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
}
[2013‑01]
Collapse
C12N 15/8243
. . . . . . .
{
involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
}
[2013‑01]
Collapse
C12N 15/8245
. . . . . . . .
{
involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis
}
[2013‑01]
C12N 15/8246
. . . . . . . . .
{
Non-starch polysaccharides, e.g. cellulose, fructans, levans
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8245

C12N 15/8247
. . . . . . . .
{
involving modified lipid metabolism, e.g. seed oil composition
}
[2013‑01]
C12N 15/8249
. . . . . . . .
{
involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life
}
[2013‑01]
C12N 15/825
. . . . . . . .
{
involving pigment biosynthesis
}
[2013‑01]
NOTE
-
Transgenic plants with altered flower morphology are also classified in this group

Collapse
. . . . . . . .
{
Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis
}
[2013‑01]
C12N 15/8253
. . . . . . . . .
{
Methionine or cysteine
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8251

C12N 15/8254
. . . . . . . . .
{
Tryptophan or lysine
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8251

C12N 15/8255
. . . . . . . .
{
involving lignin biosynthesis
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8243

Collapse
C12N 15/8257
. . . . . . .
{
for the production of primary gene products, e.g. pharmaceutical products, interferon
}
[2013‑01]
C12N 15/8258
. . . . . . . .
{
for the production of oral vaccines (antigens) or immunoglobulins
}
[2013‑01]
C12N 15/8259
. . . . . . .
{
Phytoremediation
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8242

Collapse
. . . . . .
{
with agronomic (input) traits, e.g. crop yield
}
[2013‑01]
Collapse
C12N 15/8262
. . . . . . .
{
involving plant development (not used)
}
[2013‑01]
C12N 15/8263
. . . . . . . .
{
Ablation; Apoptosis
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8261

C12N 15/8265
. . . . . . . .
{
Transgene containment, e.g. gene dispersal
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8261

C12N 15/8266
. . . . . . . .
{
Abscission; Dehiscence; Senescence
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8261

C12N 15/8267
. . . . . . . .
{
Seed dormancy, germination or sprouting
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8261

C12N 15/8269
. . . . . . . .
{
Photosynthesis
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8261

C12N 15/827
. . . . . . . .
{
Flower development or morphology, e.g. flowering promoting factor (FPF)
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8261

Collapse
C12N 15/8271
. . . . . . .
{
for stress resistance, e.g. heavy metal resistance
}
[2013‑01]
C12N 15/8273
. . . . . . . .
{
for drought, cold, salt resistance
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8271

Collapse
C12N 15/8274
. . . . . . . .
{
for herbicide resistance
}
[2013‑01]
C12N 15/8275
. . . . . . . . .
{
Glyphosate
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8274

C12N 15/8277
. . . . . . . . .
{
Phosphinotricin
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8274

C12N 15/8278
. . . . . . . . .
{
Sulfonylurea
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8274

Collapse
C12N 15/8279
. . . . . . . .
{
for biotic stress resistance, pathogen resistance, disease resistance
}
[2013‑01]
C12N 15/8281
. . . . . . . . .
{
for bacterial resistance
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8279

C12N 15/8282
. . . . . . . . .
{
for fungal resistance
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8279

C12N 15/8283
. . . . . . . . .
{
for virus resistance
}
[2013‑01]
C12N 15/8285
. . . . . . . . .
{
for nematode resistance
}
[2013‑01]
C12N 15/8286
. . . . . . . . .
{
for insect resistance
}
[2013‑01]
Collapse
C12N 15/8287
. . . . . . .
{
for fertility modification, e.g. apomixis
}
[2013‑01]
C12N 15/8289
. . . . . . . .
{
Male sterility
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8287

C12N 15/829
. . . . . . . .
{
Female sterility
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8287

Collapse
C12N 15/8291
. . . . . . .
{
Hormone-influenced development
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8261

C12N 15/8293
. . . . . . . .
{
Abscisic acid (ABA)
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8261

C12N 15/8294
. . . . . . . .
{
Auxins
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8261

C12N 15/8295
. . . . . . . .
{
Cytokinins
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8261

C12N 15/8297
. . . . . . . .
{
Gibberellins; GA3
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8261

C12N 15/8298
. . . . . . . .
{
Brassinosteroids
}
[2013‑01]
WARNING
-
Incomplete, see also C12N 15/8261

Collapse
. . . .
for animal cells [2013‑01]
Collapse
C12N 15/8509
. . . . .
{
for producing genetically modified animals, e.g. transgenic
}
[2013‑01]
NOTE
-
The purpose of the modified animal is indicated using the codes under A01K 2267/00

C12N 2015/8518
. . . . . .
{
expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
}
[2013‑01]
Collapse
C12N 2015/8527
. . . . . .
{
for producing animal models, e.g. for tests or diseases
}
[2013‑01]
Collapse
C12N 2015/8536
. . . . . . .
{
Animal models for genetic diseases
}
[2013‑01]
Collapse
C12N 2015/8545
. . . . . . . .
{
for Alzheimer''s disease
}
[2013‑01]
C12N 2015/8554
. . . . . . . . .
{
Invertebrates models for Alzheimer''s disease
}
[2013‑01]
C12N 2015/8563
. . . . . . . .
{
for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus
}
[2013‑01]
C12N 2015/8572
. . . . . . .
{
Animal models for proliferative diseases, e.g. comprising an oncogene
}
[2013‑01]
C12N 2015/8581
. . . . . . .
{
Animal models for infectious diseases, e.g. AIDS
}
[2013‑01]
C12N 2015/859
. . . . . . .
{
Animal models comprising reporter system for screening tests
}
[2013‑01]
Collapse
C12N 15/86
. . . . .
Viral vectors [2013‑01]
WARNING
-
From March 15, 2012 groups C12N 15/861 - C12N 15/869 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00-C12N 2795/00

Collapse
C12N 15/861
. . . . . .
Adenoviral vectors [2013‑01]
C12N 15/8613
. . . . . . .
{
Chimaeric vector systems comprising heterologous sequences for production of another viral vector
}
[2013‑01]
C12N 15/8616
. . . . . . .
{
Special methods for targeting systems
}
[2013‑01]
Collapse
C12N 15/863
. . . . . .
Poxviral vectors,
{
e.g. entomopoxvirus
}
[2013‑01]
C12N 15/8633
. . . . . . .
{
Avian poxviral vectors
}
[2013‑01]
C12N 15/8636
. . . . . . .
{
Vaccina virus vectors
}
[2013‑01]
Collapse
C12N 15/864
. . . . . .
Parvoviral vectors,
{
e.g. parvovirus, densovirus
}
[2013‑01]
C12N 15/8645
. . . . . . .
{
Adeno-associated virus
}
[2013‑01]
C12N 15/866
. . . . . .
Baculoviral vectors [2013‑01]
Collapse
C12N 15/867
. . . . . .
Retroviral vectors [2013‑01]
C12N 15/8673
. . . . . . .
{
Special methods for packaging systems
}
[2013‑01]
C12N 15/8676
. . . . . . .
{
Special methods for targeting systems
}
[2013‑01]
Collapse
C12N 15/869
. . . . . .
Herpesviral vectors [2013‑01]
C12N 15/8695
. . . . . . .
{
Herpes simplex virus-based vectors
}
[2013‑01]
Collapse
C12N 15/87
. .
Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation [2013‑01]
Collapse
C12N 15/873
. . .
Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos [2013‑01]
Collapse
C12N 15/877
. . . .
Techniques for producing new mammalian cloned embroys [2013‑01]
C12N 15/8771
. . . . .
{
Bovine embryos
}
[2013‑01]
C12N 15/8772
. . . . .
{
Caprine embryos
}
[2013‑01]
C12N 15/8773
. . . . .
{
Ovine embryos
}
[2013‑01]
C12N 15/8775
. . . . .
{
Murine embryos
}
[2013‑01]
C12N 15/8776
. . . . .
{
Primate embryos
}
[2013‑01]
C12N 15/8777
. . . . .
{
Rabbit embryos
}
[2013‑01]
C12N 15/8778
. . . . .
{
Swine embryos
}
[2013‑01]
C12N 15/88
. . .
using micro-encapsulation, e.g. using
{
amphiphile
}
liposome vesicle [2013‑01]
Collapse
C12N 15/89
. . .
using micro-injection [2013‑01]
C12N 15/895
. . . .
{
using biolistic methods
}
[2013‑01]
Collapse
C12N 15/90
. . .
Stable introduction of foreign DNA into chromosome [2013‑01]
Collapse
C12N 15/902
. . . .
{
using homologous recombination
}
[2013‑01]
C12N 15/905
. . . . .
{
in geasts
}
[2013‑01]
C12N 15/907
. . . . .
{
in mammalian cells
}
[2013‑01]
C12N 2303/00
Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids [2013‑01]
NOTE
-

Indexing codes of group C12N 2303/00 are only used in combination with group C12N 15/111

Collapse
Structure or type of the nucleic acid [2013‑01]
Collapse
.
Type of nucleic acid [2013‑01]
Collapse
C12N 2310/11
. .
Antisense [2013‑01]
C12N 2310/111
. . .
spanning the whole gene, or a large part of it [2013‑01]
C12N 2310/113
. . .
targeting other non-coding nucleic acids, e.g. antagomirs [2013‑01]
Collapse
C12N 2310/12
. .
catalytic nucleic acids, e.g. ribozymes [2013‑01]
C12N 2310/121
. . .
Hammerhead [2013‑01]
C12N 2310/122
. . .
Hairpin [2013‑01]
C12N 2310/123
. . .
Hepatitis delta [2013‑01]
Collapse
C12N 2310/124
. . .
based on group I or II introns [2013‑01]
C12N 2310/1241
. . . .
Tetrahymena [2013‑01]
C12N 2310/126
. . .
involving RNAse P [2013‑01]
C12N 2310/127
. . .
DNAzymes [2013‑01]
C12N 2310/128
. . .
processing or releasing ribozyme [2013‑01]
C12N 2310/13
. .
Decoys [2013‑01]
Collapse
C12N 2310/14
. .
interfering N.A. [2013‑01]
C12N 2310/141
. . .
MicroRNAs, miRNAs [2013‑01]
Collapse
C12N 2310/15
. .
Nucleic acids forming more than 2 strands, e.g. TFOs [2013‑01]
C12N 2310/151
. . .
more than 3 strands, e.g. tetrads, H-DNA [2013‑01]
C12N 2310/152
. . .
on a single-stranded target, e.g. fold-back TFOs [2013‑01]
C12N 2310/153
. . .
with the aid of a protein, e.g. recombinase [2013‑01]
C12N 2310/16
. .
Aptamers [2013‑01]
C12N 2310/17
. .
Immunomodulatory nucleic acids [2013‑01]
C12N 2310/18
. .
acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17) [2013‑01]
Collapse
.
Chemical structure [2013‑01]
Collapse
. .
of the backbone [2013‑01]
C12N 2310/311
. . .
Phosphotriesters [2013‑01]
Collapse
C12N 2310/312
. . .
Phosphonates [2013‑01]
C12N 2310/3125
. . . .
Methylphosphonates [2013‑01]
C12N 2310/313
. . .
Phosphorodithioates [2013‑01]
Collapse
C12N 2310/314
. . .
Phosphoramidates [2013‑01]
C12N 2310/3145
. . . .
with the nitrogen in 3' or 5'-position [2013‑01]
C12N 2310/315
. . .
Phosphorothioates [2013‑01]
C12N 2310/316
. . .
Phosphonothioates [2013‑01]
C12N 2310/317
. . .
with an inverted bond, e.g. a cap structure [2013‑01]
Collapse
. . .
where the PO2 is completely replaced, e.g. MMI or formacetal [2013‑01]
C12N 2310/3181
. . . .
Peptide nucleic acid, PNA [2013‑01]
C12N 2310/3183
. . . .
Diol linkers, e.g. glycols or propanediols [2013‑01]
C12N 2310/319
. . .
linked by 2'-5' linkages, i.e. having a free 3'-position [2013‑01]
Collapse
. .
of the sugar [2013‑01]
. . .
2'-O-R Modification [2013‑01]
. . .
2'-R Modification [2013‑01]
Collapse
. . .
modified ring structure [2013‑01]
C12N 2310/3231
. . . .
having an additional ring, e.g. LNA, ENA [2013‑01]
C12N 2310/3233
. . . .
Morpholino-type ring [2013‑01]
C12N 2310/3235
. . . .
having the O of the ribose replaced by another atom [2013‑01]
Collapse
. .
of the base [2013‑01]
C12N 2310/331
. . .
Universal or degenerate base [2013‑01]
C12N 2310/332
. . .
Abasic residue [2013‑01]
C12N 2310/333
. . .
Modified A [2013‑01]
Collapse
C12N 2310/334
. . .
Modified C [2013‑01]
C12N 2310/3341
. . . .
5-Methylcytosine [2013‑01]
C12N 2310/335
. . .
Modified T or U [2013‑01]
C12N 2310/336
. . .
Modified G [2013‑01]
C12N 2310/337
. . .
in alpha-anomeric form [2013‑01]
Collapse
. .
Spatial arrangement of the modifications [2013‑01]
C12N 2310/341
. . .
Gapmers, i.e. of the type ===---=== [2013‑01]
C12N 2310/342
. . .
Hemimers, i.e. of the type ====---- [2013‑01]
C12N 2310/343
. . .
having patterns, e.g. ==--==--==-- [2013‑01]
C12N 2310/344
. . .
Position-specific modifications, e.g. on every purine, at the 3'-end [2013‑01]
C12N 2310/345
. . .
having at least two different backbone modifications [2013‑01]
C12N 2310/346
. . .
having a combination of backbone and sugar modifications [2013‑01]
Collapse
C12N 2310/35
. .
Nature of the modification [2013‑01]
Collapse
C12N 2310/351
. . .
Conjugate [2013‑01]
C12N 2310/3511
. . . .
intercalating or cleaving agent [2013‑01]
C12N 2310/3513
. . . .
Protein; Peptide [2013‑01]
C12N 2310/3515
. . . .
Lipophilic moiety, e.g. cholesterol [2013‑01]
C12N 2310/3517
. . . .
Marker; Tag [2013‑01]
C12N 2310/3519
. . . .
Fusion with another nucleic acid [2013‑01]
Collapse
C12N 2310/352
. . .
linked to the nucleic acid via a carbon atom [2013‑01]
C12N 2310/3521
. . . .
Methyl [2013‑01]
C12N 2310/3523
. . . .
Allyl [2013‑01]
C12N 2310/3525
. . . .
MOE, methoxyethoxy [2013‑01]
C12N 2310/3527
. . . .
Other alkyl chain [2013‑01]
C12N 2310/3529
. . . .
Aromatic substituent [2013‑01]
C12N 2310/353
. . .
linked to the nucleic acid via an atom other than carbon [2013‑01]
C12N 2310/3531
. . .
Hydrogen [2013‑01]
C12N 2310/3533
. . .
Halogen [2013‑01]
C12N 2310/3535
. . .
Nitrogen [2013‑01]
Collapse
C12N 2310/50
.
Physical structure [2013‑01]
C12N 2310/51
. .
in polymeric form, e.g. multimers, concatemers [2013‑01]
C12N 2310/52
. .
branched [2013‑01]
Collapse
C12N 2310/53
. .
partially self-complementary or closed [2013‑01]
C12N 2310/531
. . .
Stem-loop; Hairpin [2013‑01]
C12N 2310/532
. . .
Closed or circular [2013‑01]
C12N 2310/533
. . .
having a mismatch or nick in at least one of the strands [2013‑01]
Collapse
Applications; Uses [2013‑01]
Collapse
.
in screening processes [2013‑01]
. .
for the determination of target sites, i.e. of active nucleic acids [2013‑01]
C12N 2320/12
. .
in functional genomics, i.e. for the determination of gene function [2013‑01]
. .
in a process of directed evolution, e.g. SELEX, acquiring a new function [2013‑01]
Collapse
.
Special therapeutic applications [2013‑01]
C12N 2320/31
. .
Combination therapy [2013‑01]
C12N 2320/32
. .
Special delivery means, e.g. tissue-specific [2013‑01]
C12N 2320/33
. .
Alteration of splicing [2013‑01]
C12N 2320/34
. .
Allele or polymorphism specific uses [2013‑01]
C12N 2320/35
. .
based on a specific dosage / administration regimen [2013‑01]
Collapse
.
Methods for regulating/modulating their activity [2013‑01]
C12N 2320/51
. .
modulating the chemical stability, e.g. nuclease-resistance [2013‑01]
C12N 2320/52
. .
modulating the physical stability, e.g. GC-content [2013‑01]
C12N 2320/53
. .
reducing unwanted side-effects [2013‑01]
Collapse
Production [2013‑01]
.
naturally occurring [2013‑01]
Collapse
C12N 2330/30
.
chemically synthesised [2013‑01]
C12N 2330/31
. .
Libraries, arrays [2013‑01]
Collapse
C12N 2330/50
.
Biochemical production, i.e. in a transformed host cell [2013‑01]
C12N 2330/51
. .
Specially adapted vectors [2013‑01]
Collapse
C12N 2500/00
Specific components of cell culture medium [2013‑01]
C12N 2500/02
.
Atmosphere, e.g. low oxygen conditions [2013‑01]
Collapse
C12N 2500/05
.
Inorganic components [2013‑01]
Collapse
C12N 2500/10
. .
Metals; Metal chelators (cobalamine C12N 2500/38) [2013‑01]
Collapse
C12N 2500/12
. . .
Light metals, i.e. alkali, alkaline earth, Be, Al, Mg [2013‑01]
C12N 2500/14
. . . .
Calcium; Ca chelators; Calcitonin [2013‑01]
C12N 2500/16
. . . .
Magnesium; Mg chelators [2013‑01]
Collapse
C12N 2500/20
. . .
Transition metals [2013‑01]
C12N 2500/22
. . . .
Zinc; Zn chelators (insulin-zinc complexes C12N 2501/33) [2013‑01]
Collapse
C12N 2500/24
. . . .
Iron; Fe chelators; Transferrin [2013‑01]
C12N 2500/25
. . . . .
Insulin-transferrin; Insulin-transferrin-selenium [2013‑01]
Collapse
C12N 2500/30
.
Organic components (metal chelators C12N 2500/10 ; calcitonin C12N 2500/14 ; transferrin C12N 2500/24) [2013‑01]
Collapse
C12N 2500/32
. .
Amino acids [2013‑01]
C12N 2500/33
. . .
other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine [2013‑01]
C12N 2500/34
. .
Sugars [2013‑01]
C12N 2500/35
. .
Polyols, e.g. glycerin, inositol [2013‑01]
C12N 2500/36
. .
Lipids [2013‑01]
C12N 2500/38
. .
Vitamins [2013‑01]
C12N 2500/40
. .
Nucleotides, nucleosides, bases (cyclic nucleotides C12N 2501/01 , anti-neoplasic drugs C12N 2501/06) [2013‑01]
C12N 2500/42
. .
Organic phosphate, e.g. beta glycerophosphate [2013‑01]
C12N 2500/44
. .
Thiols, e.g. mercaptoethanol [2013‑01]
C12N 2500/46
. .
Amines, e.g. putrescine [2013‑01]
C12N 2500/50
.
Soluble polymers, e.g. polyethyleneglycol (PEG) [2013‑01]
Collapse
C12N 2500/60
.
Buffer, e.g. pH regulation, osmotic pressure [2013‑01]
C12N 2500/62
. .
DMSO [2013‑01]
Collapse
C12N 2500/70
.
Undefined extracts (conditioned medium C12N 2502/00) [2013‑01]
C12N 2500/72
. .
from bacteria [2013‑01]
C12N 2500/74
. .
from fungi, e.g. yeasts [2013‑01]
C12N 2500/76
. .
from plants [2013‑01]
C12N 2500/78
. .
from protozoa [2013‑01]
Collapse
C12N 2500/80
. .
from animals [2013‑01]
C12N 2500/82
. . .
from invertebrates [2013‑01]
C12N 2500/84
. . .
from mammals [2013‑01]
Collapse
C12N 2500/90
.
Serum-free medium, which may still contain naturally-sourced components [2013‑01]
C12N 2500/92
. .
Medium free of human- or animal-derived components [2013‑01]
C12N 2500/95
. .
Protein-free medium and culture conditions [2013‑01]
C12N 2500/98
.
Xeno-free medium and culture conditions [2013‑01]
C12N 2500/99
.
Serum-free medium [2013‑01]
WARNING
-
This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to C12N 2500/90 to C12N 2500/98

Collapse
C12N 2501/00
Active agents used in cell culture processes, e.g. differentation [2013‑01]
NOTE
-
Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in C07K 14/00, but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

C12N 2501/01
.
Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin [2013‑01]
C12N 2501/02
.
Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes [2013‑01]
C12N 2501/03
.
Compounds acting on the NO pathway, e.g. nitrososarginine [2013‑01]
C12N 2501/04
.
Immunosuppressors, e.g. cyclosporin, tacrolimus [2013‑01]
Collapse
C12N 2501/05
.
Adjuvants [2013‑01]
C12N 2501/051
. .
Lipid A (MPA, MPL) [2013‑01]
C12N 2501/052
. .
Lipopolysaccharides (LPS) [2013‑01]
C12N 2501/054
. .
Muramyle peptides [2013‑01]
C12N 2501/056
. .
Immunostimulating oligonucleotides, e.g. CpG [2013‑01]
C12N 2501/06
.
Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide [2013‑01]
C12N 2501/065
.
Modulators of histone acetylation [2013‑01]
C12N 2501/07
.
Heat shock proteins [2013‑01]
Collapse
C12N 2501/10
.
Growth factors [2013‑01]
C12N 2501/105
. .
Insulin-like growth factors (IGF) [2013‑01]
C12N 2501/11
. .
Epidermal growth factor (EGF) [2013‑01]
C12N 2501/113
. .
Acidic fibroblast growth factor (aFGF, FGF-1) [2013‑01]
C12N 2501/115
. .
Basic fibroblast growth factor (bFGF, FGF-2) [2013‑01]
C12N 2501/117
. .
Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12) [2013‑01]
C12N 2501/119
. .
Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10 [2013‑01]
C12N 2501/12
. .
Hepatocyte growth factor (HGF) [2013‑01]
C12N 2501/125
. .
Stem cell factor (SCF), c-kit ligand (KL) [2013‑01]
C12N 2501/13
. .
Nerve growth factor (NGF); Brain-derived neurotrophic factor (BDNF); Cilliary neurotrophic factor (CNTF); Glial-derived neurotrophic factor (GDNF); Neurotrophins (NT); Neuregulins [2013‑01]
C12N 2501/135
. .
Platelet-derived growth factor (PDGF) [2013‑01]
C12N 2501/14
. .
Erythropoietin (EPO) [2013‑01]
C12N 2501/145
. .
Thrombopoietin (TPO) [2013‑01]
C12N 2501/148
. .
Transforming growth factor alpha (TGF-a) [2013‑01]
C12N 2501/15
. .
Transforming growth factor beta (TGF-?) [2013‑01]
C12N 2501/155
. .
Bone morphogenic proteins (BMP); Osteogenins; Osteogenic factor; Bone inducing factor [2013‑01]
C12N 2501/16
. .
Activin; Inhibin; Mullerian inhibiting substance [2013‑01]
C12N 2501/165
. .
Vascular endothelial growth factor (VEGF) [2013‑01]
C12N 2501/17
. .
Angiopoietin [2013‑01]
C12N 2501/175
. .
Cardiotrophin [2013‑01]
C12N 2501/18
. .
Liver cell growth factor (LCGF, Gly-His-Lys) [2013‑01]
C12N 2501/185
. .
Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL) [2013‑01]
C12N 2501/19
. .
Growth and differentiation factors (GDF) [2013‑01]
C12N 2501/195
. .
Heregulin, neu differentiation factor [2013‑01]
Collapse
C12N 2501/20
.
Cytokines; Chemokines [2013‑01]
C12N 2501/21
. .
Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4 [2013‑01]
C12N 2501/22
. .
Colony stimulating factors (G-CSF, GM-CSF) [2013‑01]
Collapse
C12N 2501/23
. .
Interleukins (IL) [2013‑01]
C12N 2501/2301
. . .
Interleukin-1 (IL-1) [2013‑01]
C12N 2501/2302
. . .
Interleukin-2 (IL-2) [2013‑01]
C12N 2501/2303
. . .
Interleukin-3 (IL-3) [2013‑01]
C12N 2501/2304
. . .
Interleukin-4 (IL-4) [2013‑01]
C12N 2501/2305
. . .
Interleukin-5 (IL-5) [2013‑01]
C12N 2501/2306
. . .
Interleukin-6 (IL-6) [2013‑01]
C12N 2501/2307
. . .
Interleukin-7 (IL-7) [2013‑01]
C12N 2501/2308
. . .
Interleukin-8 (IL-8) [2013‑01]
C12N 2501/2309
. . .
Interleukin-9 (IL-9) [2013‑01]
C12N 2501/231
. . .
Interleukin-10 (IL-10) [2013‑01]
C12N 2501/2311
. . .
Interleukin-11 (IL-11) [2013‑01]
C12N 2501/2312
. . .
Interleukin-12 (IL-12) [2013‑01]
C12N 2501/2313
. . .
Interleukin-13 (IL-13) [2013‑01]
C12N 2501/2314
. . .
Interleukin-14 (IL-14) [2013‑01]
C12N 2501/2315
. . .
Interleukin-15 (IL-15) [2013‑01]
C12N 2501/2316
. . .
Interleukin-16 (IL-16) [2013‑01]
C12N 2501/2317
. . .
Interleukin-17 (IL-17) [2013‑01]
C12N 2501/2318
. . .
Interleukin-18 (IL-18) [2013‑01]
C12N 2501/2319
. . .
Interleukin-19 (IL-19) [2013‑01]
C12N 2501/232
. . .
Interleukin-20 (IL-20) [2013‑01]
C12N 2501/2321
. . .
Interleukin-21 (IL-21) [2013‑01]
C12N 2501/2322
. . .
Interleukin-22 (IL-22) [2013‑01]
C12N 2501/2323
. . .
Interleukin-23 (IL-23) [2013‑01]
C12N 2501/2324
. . .
Interleukin-24 (IL-24) [2013‑01]
C12N 2501/2325
. . .
Interleukin-25 (IL-25) [2013‑01]
C12N 2501/2326
. . .
Interleukin-26 (IL-26) [2013‑01]
C12N 2501/2327
. . .
Interleukin-27 (IL-27) [2013‑01]
C12N 2501/2328
. . .
Interleukin-28 (IL-28) [2013‑01]
C12N 2501/2329
. . .
Interleukin-29 (IL-29) [2013‑01]
C12N 2501/233
. . .
Interleukin-30 (IL-30) [2013‑01]
C12N 2501/2331
. . .
Interleukin-31 (IL-31) [2013‑01]
C12N 2501/2332
. . .
Interleukin-32 (IL-32) [2013‑01]
C12N 2501/2333
. . .
Interleukin-33 (IL-33) [2013‑01]
C12N 2501/2334
. . .
Interleukin-34 (IL-34) [2013‑01]
C12N 2501/2335
. . .
Interleukin-35 (IL-35) [2013‑01]
C12N 2501/235
. . .
Leukemia inhibitory factor (LIF) [2013‑01]
C12N 2501/237
. .
Oncostatin M (OSM) [2013‑01]
C12N 2501/24
. .
Interferons (IFN) [2013‑01]
C12N 2501/25
. .
Tumour necrosing factors (TNF) [2013‑01]
C12N 2501/26
. .
Flt-3 ligand (CD135L, flk-2 ligand) [2013‑01]
Collapse
C12N 2501/30
.
Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85) [2013‑01]
C12N 2501/305
. .
Growth hormone (GH), aka. somatotropin [2013‑01]
C12N 2501/31
. .
Pituitary sex hormones, e.g. follicle-stimulating hormone (FSH), luteinising hormone (LH); Chorionic gonadotropins [2013‑01]
C12N 2501/315
. .
Prolactin [2013‑01]
C12N 2501/32
. .
Angiotensins (AT), angiotensinogen [2013‑01]
C12N 2501/33
. .
Insulin (together with transferrin C12N 2500/25 ; Insulin-like growth factors C12N 2501/105) [2013‑01]
C12N 2501/335
. .
Glucagon; Glucagon-like peptide (GLP); Exendin [2013‑01]
C12N 2501/34
. .
Calcitonin; Calcitonin-gene related peptide (CGRO); Amylin [2013‑01]
C12N 2501/345
. .
Gastrin; Cholecystokinins (CCK) [2013‑01]
C12N 2501/35
. .
Vasoactive intestinal peptide (VIP); Pituitary adenylate cyclase activating polypeptide (PACAP) [2013‑01]
C12N 2501/355
. .
Leptin [2013‑01]
C12N 2501/36
. .
Somatostatin [2013‑01]
C12N 2501/365
. .
Endothelin [2013‑01]
C12N 2501/37
. .
Parathyroid hormone (PTH) [2013‑01]
C12N 2501/375
. .
Thyroid stimulating hormone (TSH) [2013‑01]
Collapse
C12N 2501/38
. .
with nuclear receptors [2013‑01]
C12N 2501/385
. . .
of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor (PPAR) [2013‑01]
Collapse
C12N 2501/39
. . .
Steroid hormones [2013‑01]
C12N 2501/392
. . . .
Sexual steroids [2013‑01]
C12N 2501/395
. . .
Thyroid hormones [2013‑01]
Collapse
C12N 2501/40
.
Regulators of development [2013‑01]
C12N 2501/405
. .
Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases [2013‑01]
C12N 2501/41
. .
Hedgehog proteins; Cyclopamine (inhibitor) [2013‑01]
C12N 2501/415
. .
Wnt; Frizzeled [2013‑01]
C12N 2501/42
. .
Notch; Delta; Jagged; Serrate [2013‑01]
C12N 2501/48
. .
Regulators of apoptosis [2013‑01]
Collapse
C12N 2501/50
.
Cell markers; Cell surface determinants [2013‑01]
C12N 2501/505
. .
CD4; CD8 [2013‑01]
C12N 2501/51
. .
B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand) [2013‑01]
C12N 2501/515
. .
CD3, T-cell receptor complex [2013‑01]
C12N 2501/52
. .
CD40, CD40-ligand (CD154) [2013‑01]
C12N 2501/53
. .
CD2 [2013‑01]
C12N 2501/58
. .
Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand) [2013‑01]
C12N 2501/585
. .
Integrins [2013‑01]
C12N 2501/59
. .
Lectins [2013‑01]
C12N 2501/599
. .
with CD designations not provided for elsewhere [2013‑01]
Collapse
C12N 2501/60
.
Transcription factors [2013‑01]
C12N 2501/602
. .
Sox-2 [2013‑01]
C12N 2501/603
. .
Oct-3/4 [2013‑01]
C12N 2501/604
. .
Klf-4 [2013‑01]
C12N 2501/605
. .
Nanog [2013‑01]
C12N 2501/606
. .
c-Myc [2013‑01]
C12N 2501/608
. .
Lin28 [2013‑01]
C12N 2501/65
.
Micro-RNA [2013‑01]
Collapse
C12N 2501/70
.
Enzymes [2013‑01]
C12N 2501/71
. .
Oxidoreductases (EC 1.) [2013‑01]
Collapse
C12N 2501/72
. .
Transferases (EC 2.) (acetylation of histones C12N 2501/065) [2013‑01]
C12N 2501/724
. . .
Glycosyltransferases (EC 2.4.) [2013‑01]
C12N 2501/727
. . .
Kinases (EC 2.7.) [2013‑01]
Collapse
C12N 2501/73
. .
Hydrolases (EC 3.) [2013‑01]
C12N 2501/734
. . .
Proteases (EC 3.4.) [2013‑01]
Collapse
C12N 2501/80
.
Neurotransmitters; Neurohormones [2013‑01]
C12N 2501/805
. .
Acetylcholine [2013‑01]
C12N 2501/81
. .
Adrenaline [2013‑01]
C12N 2501/815
. .
Dopamine [2013‑01]
C12N 2501/82
. .
Histamine [2013‑01]
C12N 2501/825
. .
Serotonine (5-HT); Melatonine [2013‑01]
C12N 2501/83
. .
Tachykinins, e.g. substance P [2013‑01]
C12N 2501/835
. .
Neuropeptide Y (NPY); Peptide YY (PYY) [2013‑01]
C12N 2501/84
. .
Excitatory amino acids [2013‑01]
C12N 2501/845
. .
Gamma amino butyric acid (GABA) [2013‑01]
Collapse
C12N 2501/85
.
Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin [2013‑01]
C12N 2501/855
. .
Corticotropin (ACTH) [2013‑01]
C12N 2501/86
. .
Melanocyte-stimulating hormone (MSH) [2013‑01]
Collapse
C12N 2501/90
.
Polysaccharides [2013‑01]
C12N 2501/905
. .
Hyaluronic acid [2013‑01]
C12N 2501/91
. .
Heparin [2013‑01]
C12N 2501/998
.
Proteins not provided for elsewhere [2013‑01]
NOTE
-
Classification by pathway does not apply.

C12N 2501/999
.
Small molecules not provided for elsewhere [2013‑01]
NOTE
-
Classification by pathway does not apply.

Collapse
C12N 2502/00
Coculture with; Conditioned medium produced by [2013‑01]
Collapse
C12N 2502/02
.
embryonic cells [2013‑01]
C12N 2502/025
. .
extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly [2013‑01]
C12N 2502/03
.
non-embryonic pluripotent stem cells [2013‑01]
C12N 2502/04
.
germ cells [2013‑01]
Collapse
C12N 2502/07
.
endocrine cells [2013‑01]
C12N 2502/072
. .
adrenal cells [2013‑01]
C12N 2502/074
. .
pinealocytes [2013‑01]
C12N 2502/076
. .
pituitary cells [2013‑01]
C12N 2502/078
. .
thyroid, parathyroid cells [2013‑01]
Collapse
C12N 2502/08
.
cells of the nervous system [2013‑01]
C12N 2502/081
. .
neurons [2013‑01]
C12N 2502/083
. .
sensory transducers [2013‑01]
C12N 2502/085
. .
eye cells [2013‑01]
C12N 2502/086
. .
glial cells [2013‑01]
C12N 2502/088
. .
neural stem cells [2013‑01]
Collapse
C12N 2502/09
.
epidermal cells, skin cells, oral mucosa cells [2013‑01]
C12N 2502/091
. .
melanocytes [2013‑01]
C12N 2502/092
. .
hair cells [2013‑01]
C12N 2502/094
. .
keratinocytes [2013‑01]
C12N 2502/095
. .
mammary cells [2013‑01]
C12N 2502/097
. .
oral mucosa cells [2013‑01]
C12N 2502/098
. .
cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands [2013‑01]
Collapse
C12N 2502/11
.
blood or immune system cells [2013‑01]
C12N 2502/1107
. .
B cells [2013‑01]
C12N 2502/1114
. .
T cells [2013‑01]
C12N 2502/1121
. .
Dendritic cells [2013‑01]
C12N 2502/1128
. .
Erythrocytes [2013‑01]
C12N 2502/1135
. .
Granulocytes [2013‑01]
C12N 2502/1142
. .
Osteoclasts [2013‑01]
C12N 2502/115
. .
Platelets, megakaryocytes [2013‑01]
C12N 2502/1157
. .
Monocytes, macrophages [2013‑01]
C12N 2502/1164
. .
NK cells [2013‑01]
C12N 2502/1171
. .
Haematopoietic stem cells [2013‑01]
C12N 2502/1178
. .
Spleen cells [2013‑01]
C12N 2502/1185
. .
Thymus cells [2013‑01]
C12N 2502/1192
. .
Lymphatic cells [2013‑01]
Collapse
C12N 2502/13
.
connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts" [2013‑01]
C12N 2502/1305
. .
Adipocytes [2013‑01]
C12N 2502/1311
. .
Osteocytes, osteoblasts, odontoblasts [2013‑01]
C12N 2502/1317
. .
Chondrocytes [2013‑01]
C12N 2502/1323
. .
Adult fibroblasts [2013‑01]
C12N 2502/1329
. .
Cardiomyocytes [2013‑01]
C12N 2502/1335
. .
Skeletal muscle cells, myocytes, myoblasts, myotubes [2013‑01]
C12N 2502/1341
. .
Tenocytes, cells from tendons and ligaments [2013‑01]
C12N 2502/1347
. .
Smooth muscle cells [2013‑01]
Collapse
C12N 2502/1352
. .
Mesenchymal stem cells [2013‑01]
C12N 2502/1358
. . .
Bone marrow mesenchymal stem cells (BM-MSC) [2013‑01]
C12N 2502/1364
. . .
Dental pulp stem cells, dental follicle stem cells [2013‑01]
C12N 2502/137
. . .
Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood [2013‑01]
C12N 2502/1376
. . .
Mesenchymal stem cells from hair follicles [2013‑01]
C12N 2502/1382
. . .
Adipose-derived stem cells (ADSC), adipose stromal stem cells [2013‑01]
C12N 2502/1388
. . .
Mesenchymal stem cells from other natural sources [2013‑01]
C12N 2502/1394
. .
Bone marrow stromal cells; whole marrow [2013‑01]
C12N 2502/14
.
hepatocytes [2013‑01]
C12N 2502/16
.
fibroblasts [2013‑01]
WARNING
-
This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to subgroups of C12N 2502/13

C12N 2502/21
.
bone marrow stromal cells [2013‑01]
WARNING
-
This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to subgroups of C12N 2502/13

C12N 2502/22
.
pancreatic cells [2013‑01]
C12N 2502/23
.
Gastro-intestinal tract cells [2013‑01]
Collapse
C12N 2502/24
.
Genital tract cells, non-germinal cells from gonads [2013‑01]
C12N 2502/243
. .
Cells of the female genital tract , non-germinal ovarian cells [2013‑01]
C12N 2502/246
. .
Cells of the male genital tract, non-germinal testis cells [2013‑01]
Collapse
C12N 2502/25
.
Urinary tract cells, renal cells [2013‑01]
C12N 2502/253
. .
Bladder cells [2013‑01]
C12N 2502/256
. .
Renal cells [2013‑01]
C12N 2502/27
.
Lung cells, respiratory tract cells [2013‑01]
C12N 2502/28
.
Vascular endothelial cells [2013‑01]
C12N 2502/30
.
tumour cells [2013‑01]
C12N 2502/45
.
Artificially induced pluripotent stem cells [2013‑01]
C12N 2502/50
.
invertebrate cells [2013‑01]
C12N 2502/70
.
Non-animal cells [2013‑01]
C12N 2502/99
.
genetically modified cells [2013‑01]
NOTE
-
Use C12N 2501/00 to index the expressed products.

Collapse
C12N 2503/00
Use of cells in diagnostics [2013‑01]
C12N 2503/02
.
Drug screening [2013‑01]
Collapse
C12N 2503/04
.
Screening or testing on artificial tissues [2013‑01]
C12N 2503/06
. .
Screening or testing on artificial skin [2013‑01]
Collapse
C12N 2506/00
Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells [2013‑01]
NOTE
-
This scheme indexes the starting point of a differentiation process and is used in combination with classification in C12N 5/06 for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

Collapse
C12N 2506/02
.
from embryonic cells [2013‑01]
C12N 2506/025
. .
from extra-embryonic cells, e.g. trophoblast, placenta [2013‑01]
C12N 2506/03
.
from non-embryonic pluripotent stem cells [2013‑01]
C12N 2506/04
.
from germ cells [2013‑01]
Collapse
C12N 2506/07
.
from endocrine cells [2013‑01]
C12N 2506/072
. .
from adrenal cells [2013‑01]
C12N 2506/074
. .
from pinealocytes [2013‑01]
C12N 2506/076
. .
from pituitary cells [2013‑01]
C12N 2506/078
. .
from thyroid, parathyroid cells [2013‑01]
C12N 2506/08
.
from cells of the nervous system [2013‑01]
Collapse
C12N 2506/09
.
from epidermal cells, from skin cells, from oral mucosa cells [2013‑01]
C12N 2506/091
. .
from melanocytes [2013‑01]
C12N 2506/092
. .
from hair cells [2013‑01]
C12N 2506/094
. .
from keratinocytes [2013‑01]
C12N 2506/095
. .
from mammary cells [2013‑01]
C12N 2506/097
. .
from oral mucosa cells [2013‑01]
C12N 2506/098
. .
from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands [2013‑01]
Collapse
C12N 2506/11
.
from blood or immune system cells [2013‑01]
C12N 2506/115
. .
from monocytes, from macrophages [2013‑01]
Collapse
C12N 2506/13
.
from connective tissue cells, from mesenchymal cells [2013‑01]
C12N 2506/1307
. .
from adult fibroblasts [2013‑01]
C12N 2506/1315
. .
from cardiomyocytes [2013‑01]
C12N 2506/1323
. .
from skeletal muscle cells [2013‑01]
C12N 2506/133
. .
from tenocytes [2013‑01]
C12N 2506/1338
. .
from smooth muscle cells [2013‑01]
Collapse
C12N 2506/1346
. .
from mesenchymal stem cells [2013‑01]
C12N 2506/1353
. . .
from bone marrow mesenchymal stem cells (BM-MSC) [2013‑01]
C12N 2506/1361
. . .
from dental pulp or dental follicle stem cells [2013‑01]
C12N 2506/1369
. . .
from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood [2013‑01]
C12N 2506/1376
. . .
from mesenchymal stem cells derived from hair follicles [2013‑01]
C12N 2506/1384
. . .
from adipose-derived stem cells (ADSC), from adipose stromal stem cells [2013‑01]
C12N 2506/1392
. . .
from mesenchymal stem cells from other natural sources [2013‑01]
C12N 2506/14
.
from hepatocytes [2013‑01]
C12N 2506/21
.
from bone marrow stromal cells; from mesenchymal stem cells [2013‑01]
WARNING
-
This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to subgroups of C12N 2502/13

C12N 2506/22
.
from pancreatic cells [2013‑01]
C12N 2506/23
.
from cells of the gastro-intestinal tract [2013‑01]
Collapse
C12N 2506/24
.
from cells of the genital tract, from non-germinal gonad cells [2013‑01]
C12N 2506/243
. .
from cells of the female genital tract cells, from non-germinal ovarian cells [2013‑01]
C12N 2506/246
. .
from cells of the male genital tract cells, from non-germinal testis cells [2013‑01]
C12N 2506/25
.
from renal cells, from cells of the urinary tract [2013‑01]
C12N 2506/27
.
from lung cells, from cells of the respiratory tract [2013‑01]
C12N 2506/28
.
from vascular endothelial cells [2013‑01]
C12N 2506/30
.
from cancer cells, e.g. reversion of tumour cells [2013‑01]
NOTE
-
Unless the tumourigenic phenotype is totally reversed, the end product is still classified under C12N 5/0693 .

C12N 2506/45
.
from artificially induced pluripotent stem cells [2013‑01]
Collapse
C12N 2509/00
Methods for the dissociation of cells, e.g. specific use of enzymes [2013‑01]
C12N 2509/10
.
Mechanical dissociation [2013‑01]
Collapse
C12N 2510/00
Genetically modified cells [2013‑01]
C12N 2510/02
.
Cells for production [2013‑01]
C12N 2510/04
.
Immortalised cells [2013‑01]
C12N 2511/00
Cells for large scale production [2013‑01]
C12N 2513/00
3D culture [2013‑01]
Collapse
C12N 2517/00
Cells related to new breeds of animals [2013‑01]
C12N 2517/02
.
Cells from transgenic animals [2013‑01]
C12N 2517/04
.
Cells produced using nuclear transfer [2013‑01]
C12N 2517/10
.
Conditioning of cells for in vitro fecondation or nuclear transfer [2013‑01]
Collapse
C12N 2521/00
Culture process characterised by the use of hydrostatic pressure, flow or shear forces [2013‑01]
C12N 2521/10
.
Sound, e.g. ultrasounds [2013‑01]
C12N 2523/00
Culture process characterised by temperature [2013‑01]
C12N 2525/00
Culture process characterised by gravity, e.g. microgravity [2013‑01]
C12N 2527/00
Culture process characterised by the use of mechanical forces, e.g. strain, vibration [2013‑01]
Collapse
C12N 2529/00
Culture process characterised by the use of electromagnetic stimulation [2013‑01]
C12N 2529/10
.
Stimulation by light [2013‑01]
C12N 2531/00
Microcarriers [2013‑01]
Collapse
C12N 2533/00
Supports or coatings for cell culture, characterised by material [2013‑01]
Collapse
C12N 2533/10
.
Mineral substrates [2013‑01]
C12N 2533/12
. .
Glass [2013‑01]
C12N 2533/14
. .
Ceramic [2013‑01]
C12N 2533/18
. .
Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells [2013‑01]
C12N 2533/20
.
Small organic molecules [2013‑01]
Collapse
C12N 2533/30
.
Synthetic polymers (thermoreactive polymers, e.g. PNIPAm, C12N 2539/10) [2013‑01]
C12N 2533/32
. .
Polylysine, polyornithine [2013‑01]
C12N 2533/40
. .
Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers [2013‑01]
Collapse
C12N 2533/50
.
Proteins [2013‑01]
C12N 2533/52
. .
Fibronectin; Laminin [2013‑01]
C12N 2533/54
. .
Collagen; Gelatin [2013‑01]
C12N 2533/56
. .
Fibrin; Thrombin [2013‑01]
Collapse
C12N 2533/70
.
Polysaccharides [2013‑01]
C12N 2533/72
. .
Chitin, chitosan [2013‑01]
C12N 2533/74
. .
Alginate [2013‑01]
C12N 2533/76
. .
Agarose, agar-agar [2013‑01]
C12N 2533/78
. .
Cellulose [2013‑01]
C12N 2533/80
. .
Hyaluronan [2013‑01]
Collapse
C12N 2533/90
.
Substrates of biological origin, e.g. extracellular matrix, decellularised tissue [2013‑01]
C12N 2533/92
. .
Amnion; Decellularised dermis or mucosa [2013‑01]
Collapse
C12N 2535/00
Supports or coatings for cell culture characterised by topography [2013‑01]
C12N 2535/10
.
Patterned coating [2013‑01]
Collapse
C12N 2537/00
Supports and/or coatings for cell culture characterised by physical or chemical treatment [2013‑01]
C12N 2537/10
.
Cross-linking [2013‑01]
Collapse
C12N 2539/00
Supports and/or coatings for cell culture characterised by properties [2013‑01]
C12N 2539/10
.
Coating allowing for selective detachment of cells, e.g. thermoreactive coating [2013‑01]
C12N 2700/00
Viruses [2013‑01]
Collapse
C12N 2710/00
dsDNA Viruses (not used) [2013‑01]
Collapse
C12N 2710/00011
.
dsDNA Viruses [2013‑01]
C12N 2710/00021
. .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/00022
. .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/00023
. .
Virus like particles [VLP] [2013‑01]
C12N 2710/00031
. .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/00032
. .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/00033
. .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/00034
. .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/00041
. .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/00042
. . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/00043
. . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/00044
. . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/00045
. . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/00051
. .
Methods of production or purification of viral material [2013‑01]
C12N 2710/00052
. . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/00061
. .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/00062
. . .
by genetic engineering [2013‑01]
C12N 2710/00063
. . .
by chemical treatment [2013‑01]
C12N 2710/00064
. . .
by serial passage [2013‑01]
C12N 2710/00071
. .
Demonstrated in vivo effect [2013‑01]
C12N 2710/00088
. .
For redistribution [2013‑01]
Collapse
C12N 2710/10011
. .
Adenoviridae [2013‑01]
C12N 2710/10021
. . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/10022
. . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/10023
. . .
Virus like particles [VLP] [2013‑01]
C12N 2710/10031
. . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/10032
. . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/10033
. . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/10034
. . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/10041
. . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/10042
. . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/10043
. . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/10044
. . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/10045
. . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/10051
. . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/10052
. . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/10061
. . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/10062
. . . .
by genetic engineering [2013‑01]
C12N 2710/10063
. . . .
by chemical treatment [2013‑01]
C12N 2710/10064
. . . .
by serial passage [2013‑01]
C12N 2710/10071
. . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/10088
. . .
For redistribution [2013‑01]
Collapse
C12N 2710/10111
. . .
Atadenovirus, e.g. ovine adenovirus D [2013‑01]
C12N 2710/10121
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/10122
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/10123
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/10131
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/10132
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/10133
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/10134
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/10141
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/10142
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/10143
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/10144
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/10145
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/10151
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/10152
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/10161
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/10162
. . . . .
by genetic engineering [2013‑01]
C12N 2710/10163
. . . . .
by chemical treatment [2013‑01]
C12N 2710/10164
. . . . .
by serial passage [2013‑01]
C12N 2710/10171
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/10188
. . . .
For redistribution [2013‑01]
Collapse
C12N 2710/10211
. . .
Aviadenovirus, e.g. fowl adenovirus A [2013‑01]
C12N 2710/10221
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/10222
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/10223
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/10231
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/10232
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/10233
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/10234
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/10241
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/10242
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/10243
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/10244
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/10245
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/10251
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/10252
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/10261
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/10262
. . . . .
by genetic engineering [2013‑01]
C12N 2710/10263
. . . . .
by chemical treatment [2013‑01]
C12N 2710/10264
. . . . .
by serial passage [2013‑01]
C12N 2710/10271
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/10288
. . . .
For redistribution [2013‑01]
Collapse
C12N 2710/10311
. . .
Mastadenovirus, e.g. human or simian adenoviruses [2013‑01]
C12N 2710/10321
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/10322
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/10323
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/10331
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/10332
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/10333
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/10334
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/10341
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/10342
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/10343
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/10344
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/10345
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/10351
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/10352
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/10361
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/10362
. . . . .
by genetic engineering [2013‑01]
C12N 2710/10363
. . . . .
by chemical treatment [2013‑01]
C12N 2710/10364
. . . . .
by serial passage [2013‑01]
C12N 2710/10371
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/10388
. . . .
For redistribution [2013‑01]
Collapse
C12N 2710/12011
. .
Asfarviridae [2013‑01]
C12N 2710/12021
. . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/12022
. . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/12023
. . .
Virus like particles [VLP] [2013‑01]
C12N 2710/12031
. . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/12032
. . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/12033
. . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/12034
. . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/12041
. . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/12042
. . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/12043
. . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/12044
. . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/12045
. . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/12051
. . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/12052
. . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/12061
. . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/12062
. . . .
by genetic engineering [2013‑01]
C12N 2710/12063
. . . .
by chemical treatment [2013‑01]
C12N 2710/12064
. . . .
by serial passage [2013‑01]
C12N 2710/12071
. . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/12088
. . .
For redistribution [2013‑01]
Collapse
C12N 2710/14011
. .
Baculoviridae [2013‑01]
C12N 2710/14021
. . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/14022
. . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/14023
. . .
Virus like particles [VLP] [2013‑01]
C12N 2710/14031
. . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/14032
. . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/14033
. . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/14034
. . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/14041
. . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/14042
. . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/14043
. . . .
viral genome or elements thereof as genetic vectore [2013‑01]
C12N 2710/14044
. . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/14045
. . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/14051
. . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/14052
. . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/14061
. . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/14062
. . . .
by genetic engineering [2013‑01]
C12N 2710/14063
. . . .
by chemical treatment [2013‑01]
C12N 2710/14064
. . . .
by serial passage [2013‑01]
C12N 2710/14071
. . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/14088
. . .
For redistribution [2013‑01]
Collapse
C12N 2710/14111
. . .
Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus [2013‑01]
C12N 2710/14121
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/14122
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/14123
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/14131
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/14132
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/14133
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/14134
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/14141
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/14142
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/14143
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/14144
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/14145
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/14151
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/14152
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/14161
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/14162
. . . . .
by genetic engineering [2013‑01]
C12N 2710/14163
. . . . .
by chemical treatment [2013‑01]
C12N 2710/14164
. . . . .
by serial passage [2013‑01]
C12N 2710/14171
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/14188
. . . .
For redistribution [2013‑01]
Collapse
C12N 2710/16011
. .
Herpesviridae [2013‑01]
C12N 2710/16021
. . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/16022
. . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/16023
. . .
Virus like particles [VLP] [2013‑01]
C12N 2710/16031
. . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/16032
. . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/16033
. . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/16034
. . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/16041
. . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/16042
. . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/16043
. . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/16044
. . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/16045
. . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/16051
. . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/16052
. . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/16061
. . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/16062
. . . .
by genetic engineering [2013‑01]
C12N 2710/16063
. . . .
by chemical treatment [2013‑01]
C12N 2710/16064
. . . .
by serial passage [2013‑01]
C12N 2710/16071
. . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/16088
. . .
For redistribution [2013‑01]
Collapse
C12N 2710/16111
. . .
Cytomegalovirus, e.g. human herpesvirus 5 [2013‑01]
C12N 2710/16121
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/16122
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/16123
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/16131
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/16132
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/16133
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/16134
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/16141
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/16142
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/16143
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/16144
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/16145
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/16151
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/16152
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/16161
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/16162
. . . . .
by genetic engineering [2013‑01]
C12N 2710/16163
. . . . .
by chemical treatment [2013‑01]
C12N 2710/16164
. . . . .
by serial passage [2013‑01]
C12N 2710/16171
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/16188
. . . .
For redistribution [2013‑01]
Collapse
C12N 2710/16211
. . .
Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus [2013‑01]
C12N 2710/16221
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequencess [2013‑01]
C12N 2710/16222
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/16223
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/16231
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/16232
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/16233
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/16234
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/16241
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/16242
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/16243
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/16244
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/16245
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/16251
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/16252
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/16261
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/16262
. . . . .
by genetic engineering [2013‑01]
C12N 2710/16263
. . . . .
by chemical treatment [2013‑01]
C12N 2710/16264
. . . . .
by serial passage [2013‑01]
C12N 2710/16271
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/16288
. . . .
For redistribution [2013‑01]
Collapse
C12N 2710/16311
. . .
Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV [2013‑01]
C12N 2710/16321
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/16322
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/16323
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/16331
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/16332
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/16333
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/16334
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/16341
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/16342
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/16343
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/16344
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/16345
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/16351
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/16352
. . . . .
relating to complementin g cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/16361
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/16362
. . . . .
by genetic engineering [2013‑01]
C12N 2710/16363
. . . . .
by chemical treatment [2013‑01]
C12N 2710/16364
. . . . .
by serial passage [2013‑01]
C12N 2710/16371
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/16388
. . . .
For redistribution [2013‑01]
Collapse
C12N 2710/16411
. . .
Rhadinovirus, e.g. human herpesvirus 8 [2013‑01]
C12N 2710/16421
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/16422
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/16423
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/16431
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/16432
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/16433
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/16434
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/16441
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/16442
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/16443
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/16444
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/16445
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/16451
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/16452
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/16461
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/16462
. . . . .
by genetic engineering [2013‑01]
C12N 2710/16463
. . . . .
by chemical treatment [2013‑01]
C12N 2710/16464
. . . . .
by serial passage [2013‑01]
C12N 2710/16471
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/16488
. . . .
For redistribution [2013‑01]
Collapse
C12N 2710/16511
. . .
Roseolovirus, e.g. human herpesvirus 6, 7 [2013‑01]
C12N 2710/16521
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/16522
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/16523
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/16531
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/16532
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/16533
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/16534
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral [2013‑01]
Collapse
C12N 2710/16541
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/16542
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/16543
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/16544
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/16545
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/16551
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/16552
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/16561
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/16562
. . . . .
by genetic engineering [2013‑01]
C12N 2710/16563
. . . . .
by chemical treatment [2013‑01]
C12N 2710/16564
. . . . .
by serial passage [2013‑01]
C12N 2710/16571
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/16588
. . . .
For redistribution [2013‑01]
Collapse
C12N 2710/16611
. . .
Simplexvirus, e.g. human herpesvirus 1, 2 [2013‑01]
C12N 2710/16621
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/16622
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/16623
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/16631
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/16632
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/16633
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/16634
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/16641
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/16642
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/16643
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/16644
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/16645
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/16651
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/16652
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/16661
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/16662
. . . . .
by genetic engineering [2013‑01]
C12N 2710/16663
. . . . .
by chemical treatment [2013‑01]
C12N 2710/16664
. . . . .
by serial passage [2013‑01]
C12N 2710/16671
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/16688
. . . .
For redistribution [2013‑01]
Collapse
C12N 2710/16711
. . .
Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies [2013‑01]
C12N 2710/16721
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/16722
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/16723
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/16731
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/16732
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/16733
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/16734
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/16741
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/16742
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/16743
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/16744
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/16745
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/16751
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/16752
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/16761
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/16762
. . . . .
by genetic engineering [2013‑01]
C12N 2710/16763
. . . . .
by chemical treatment [2013‑01]
C12N 2710/16764
. . . . .
by serial passage [2013‑01]
C12N 2710/16771
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/16788
. . . .
For redistribution [2013‑01]
Collapse
C12N 2710/18011
. .
Nimaviridae [2013‑01]
C12N 2710/18021
. . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/18022
. . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/18023
. . .
Virus like particles [VLP] [2013‑01]
C12N 2710/18031
. . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/18032
. . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/18033
. . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/18034
. . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/18041
. . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/18042
. . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/18043
. . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/18044
. . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/18045
. . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/18051
. . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/18052
. . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/18061
. . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/18062
. . . .
by genetic engineering [2013‑01]
C12N 2710/18063
. . . .
by chemical treatment [2013‑01]
C12N 2710/18064
. . . .
by serial passage [2013‑01]
C12N 2710/18071
. . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/18088
. . .
For redistribution [2013‑01]
Collapse
C12N 2710/20011
. .
Papillomaviridae [2013‑01]
C12N 2710/20021
. . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/20022
. . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/20023
. . .
Virus like particles [VLP] [2013‑01]
C12N 2710/20031
. . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/20032
. . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/20033
. . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/20034
. . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/20041
. . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/20042
. . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/20043
. . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/20044
. . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/20045
. . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/20051
. . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/20052
. . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/20061
. . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/20062
. . . .
by genetic engineering [2013‑01]
C12N 2710/20063
. . . .
by chemical treatment [2013‑01]
C12N 2710/20064
. . . .
by serial passage [2013‑01]
C12N 2710/20071
. . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/20088
. . .
For redistribution [2013‑01]
Collapse
C12N 2710/22011
. .
Polyomaviridae, e.g. polyoma, SV40, JC [2013‑01]
C12N 2710/22021
. . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/22022
. . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/22023
. . .
Virus like particles [VLP] [2013‑01]
C12N 2710/22031
. . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/22032
. . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/22033
. . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/22034
. . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/22041
. . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/22042
. . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/22043
. . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/22044
. . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/22045
. . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/22051
. . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/22052
. . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/22061
. . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/22062
. . . .
by genetic engineering [2013‑01]
C12N 2710/22063
. . . .
by chemical treatment [2013‑01]
C12N 2710/22064
. . . .
by serial passage [2013‑01]
C12N 2710/22071
. . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/22088
. . .
For redistribution [2013‑01]
Collapse
C12N 2710/24011
. .
Poxviridae [2013‑01]
C12N 2710/24021
. . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/24022
. . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/24023
. . .
Virus like particles [VLP] [2013‑01]
C12N 2710/24031
. . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/24032
. . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/24033
. . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/24034
. . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/24041
. . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/24042
. . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/24043
. . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/24044
. . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/24045
. . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/24051
. . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/24052
. . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/24061
. . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/24062
. . . .
by genetic engineering [2013‑01]
C12N 2710/24063
. . . .
by chemical treatment [2013‑01]
C12N 2710/24064
. . . .
by serial passage [2013‑01]
C12N 2710/24071
. . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/24088
. . .
For redistribution [2013‑01]
Collapse
C12N 2710/24111
. . .
Orthopoxvirus, e.g. vaccinia virus, variola [2013‑01]
C12N 2710/24121
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/24122
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/24123
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/24131
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/24132
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/24133
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/24134
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/24141
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/24142
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/24143
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/24144
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/24145
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/24151
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/24152
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/24161
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/24162
. . . . .
by genetic engineering [2013‑01]
C12N 2710/24163
. . . . .
by chemical treatment [2013‑01]
C12N 2710/24164
. . . . .
by serial passage [2013‑01]
C12N 2710/24171
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/24188
. . . .
For redistribution [2013‑01]
Collapse
C12N 2710/24211
. . .
Parapoxvirus, e.g. Orf virus [2013‑01]
C12N 2710/24221
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2710/24222
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2710/24223
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2710/24231
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2710/24232
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2710/24233
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2710/24234
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2710/24241
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2710/24242
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2710/24243
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2710/24244
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2710/24245
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2710/24251
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2710/24252
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2710/24261
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2710/24262
. . . . .
by genetic engineering [2013‑01]
C12N 2710/24263
. . . . .
by chemical treatment [2013‑01]
C12N 2710/24264
. . . . .
by serial passage [2013‑01]
C12N 2710/24271
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2710/24288
. . . .
For redistribution [2013‑01]
Collapse
C12N 2720/00
dsRNA Viruses (not used) [2013‑01]
Collapse
C12N 2720/00011
.
dsRNA Viruses [2013‑01]
C12N 2720/00021
. .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2720/00022
. .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2720/00023
. .
Virus like particles [VLP] [2013‑01]
C12N 2720/00031
. .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2720/00032
. .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2720/00033
. .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2720/00034
. .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2720/00041
. .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2720/00042
. . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2720/00043
. . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2720/00044
. . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2720/00045
. . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2720/00051
. .
Methods of production or purification of viral material [2013‑01]
C12N 2720/00052
. . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2720/00061
. .
Methods of inactivation or attenuation [2013‑01]
C12N 2720/00062
. . .
by genetic engineering [2013‑01]
C12N 2720/00063
. . .
by chemical treatment [2013‑01]
C12N 2720/00064
. . .
by serial passage [2013‑01]
C12N 2720/00071
. .
Demonstrated in vivo effect [2013‑01]
C12N 2720/00088
. .
For redistribution [2013‑01]
Collapse
C12N 2720/10011
. .
Birnaviridae [2013‑01]
C12N 2720/10021
. . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2720/10022
. . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2720/10023
. . .
Virus like particles [VLP] [2013‑01]
C12N 2720/10031
. . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2720/10032
. . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2720/10033
. . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2720/10034
. . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2720/10041
. . .
Use of virus, viral particle or viral elements as a vectorn [2013‑01]
C12N 2720/10042
. . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2720/10043
. . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2720/10044
. . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2720/10045
. . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2720/10051
. . .
Methods of production or purification of viral material [2013‑01]
C12N 2720/10052
. . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2720/10061
. . .
Methods of inactivation or attenuation [2013‑01]
C12N 2720/10062
. . . .
by genetic engineering [2013‑01]
C12N 2720/10063
. . . .
by chemical treatment [2013‑01]
C12N 2720/10064
. . . .
by serial passage [2013‑01]
C12N 2720/10071
. . .
Demonstrated in vivo effect [2013‑01]
C12N 2720/10088
. . .
For redistribution [2013‑01]
Collapse
C12N 2720/12011
. .
Reoviridae [2013‑01]
C12N 2720/12021
. . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2720/12022
. . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2720/12023
. . .
Virus like particles [VLP] [2013‑01]
C12N 2720/12031
. . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2720/12032
. . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2720/12033
. . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2720/12034
. . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2720/12041
. . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2720/12042
. . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2720/12043
. . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2720/12044
. . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2720/12045
. . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2720/12051
. . .
Methods of production or purification of viral material [2013‑01]
C12N 2720/12052
. . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2720/12061
. . .
Methods of inactivation or attenuation [2013‑01]
C12N 2720/12062
. . . .
by genetic engineering [2013‑01]
C12N 2720/12063
. . . .
by chemical treatment [2013‑01]
C12N 2720/12064
. . . .
by serial passage [2013‑01]
C12N 2720/12071
. . .
Demonstrated in vivo effect [2013‑01]
C12N 2720/12088
. . .
For redistribution [2013‑01]
Collapse
C12N 2720/12111
. . .
Orbivirus, e.g. bluetongue virus [2013‑01]
C12N 2720/12121
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2720/12122
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2720/12123
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2720/12131
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2720/12132
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2720/12133
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2720/12134
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2720/12141
. . . .
Use of virus, viral particle or viral elements as a vectorn [2013‑01]
C12N 2720/12142
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2720/12143
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2720/12144
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2720/12145
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2720/12151
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2720/12152
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2720/12161
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2720/12162
. . . . .
by genetic engineering [2013‑01]
C12N 2720/12163
. . . . .
by chemical treatment [2013‑01]
C12N 2720/12164
. . . . .
by serial passage [2013‑01]
C12N 2720/12171
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2720/12188
. . . .
For redistribution [2013‑01]
Collapse
C12N 2720/12211
. . .
Orthoreovirus, e.g. mammalian orthoreovirus [2013‑01]
C12N 2720/12221
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2720/12222
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2720/12223
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2720/12231
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2720/12232
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2720/12233
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2720/12234
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2720/12241
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2720/12242
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2720/12243
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2720/12244
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2720/12245
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2720/12251
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2720/12252
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2720/12261
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2720/12262
. . . . .
by genetic engineering [2013‑01]
C12N 2720/12263
. . . . .
by chemical treatment [2013‑01]
C12N 2720/12264
. . . . .
by serial passage [2013‑01]
C12N 2720/12271
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2720/12288
. . . .
For redistribution [2013‑01]
Collapse
C12N 2720/12311
. . .
Rotavirus, e.g. rotavirus A [2013‑01]
C12N 2720/12321
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2720/12322
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2720/12323
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2720/12331
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2720/12332
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2720/12333
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2720/12334
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2720/12341
. . . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2720/12342
. . . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2720/12343
. . . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2720/12344
. . . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2720/12345
. . . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2720/12351
. . . .
Methods of production or purification of viral material [2013‑01]
C12N 2720/12352
. . . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2720/12361
. . . .
Methods of inactivation or attenuation [2013‑01]
C12N 2720/12362
. . . . .
by genetic engineering [2013‑01]
C12N 2720/12363
. . . . .
by chemical treatment [2013‑01]
C12N 2720/12364
. . . . .
by serial passage [2013‑01]
C12N 2720/12371
. . . .
Demonstrated in vivo effect [2013‑01]
C12N 2720/12388
. . . .
For redistribution [2013‑01]
Collapse
C12N 2730/00
Reverse Transcribing DNA Viruses (not used) [2013‑01]
Collapse
C12N 2730/00011
.
Reverse Transcribing DNA Viruses [2013‑01]
C12N 2730/00021
. .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2730/00022
. .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2730/00023
. .
Virus like particles [VLP] [2013‑01]
C12N 2730/00031
. .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2730/00032
. .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2730/00033
. .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2730/00034
. .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2730/00041
. .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2730/00042
. . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2730/00043
. . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2730/00044
. . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2730/00045
. . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2730/00051
. .
Methods of production or purification of viral material [2013‑01]
C12N 2730/00052
. . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2730/00061
. .
Methods of inactivation or attenuation [2013‑01]
C12N 2730/00062
. . .
by genetic engineering [2013‑01]
C12N 2730/00063
. . .
by chemical treatment [2013‑01]
C12N 2730/00064
. . .
by serial passage [2013‑01]
C12N 2730/00071
. .
Demonstrated in vivo effect [2013‑01]
C12N 2730/00088
. .
For redistribution [2013‑01]
Collapse
C12N 2730/10011
. .
Hepadnaviridae [2013‑01]
C12N 2730/10021
. . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2730/10022
. . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2730/10023
. . .
Virus like particles [VLP] [2013‑01]
C12N 2730/10031
. . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2730/10032
. . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2730/10033
. . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2730/10034
. . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]
Collapse
C12N 2730/10041
. . .
Use of virus, viral particle or viral elements as a vector [2013‑01]
C12N 2730/10042
. . . .
virus or viral particle as vehicle, e.g. encapsulating small organic molecule [2013‑01]
C12N 2730/10043
. . . .
viral genome or elements thereof as genetic vector [2013‑01]
C12N 2730/10044
. . . .
Chimeric viral vector comprising heterologous viral elements for production of another viral vector [2013‑01]
C12N 2730/10045
. . . .
Special targeting system for viral vectors [2013‑01]
Collapse
C12N 2730/10051
. . .
Methods of production or purification of viral material [2013‑01]
C12N 2730/10052
. . . .
relating to complementing cells and packaging systems for producing virus or viral particles [2013‑01]
Collapse
C12N 2730/10061
. . .
Methods of inactivation or attenuation [2013‑01]
C12N 2730/10062
. . . .
by genetic engineering [2013‑01]
C12N 2730/10063
. . . .
by chemical treatment [2013‑01]
C12N 2730/10064
. . . .
by serial passage [2013‑01]
C12N 2730/10071
. . .
Demonstrated in vivo effect [2013‑01]
C12N 2730/10088
. . .
For redistribution [2013‑01]
Collapse
C12N 2730/10111
. . .
Orthohepadnavirus, e.g. hepatitis B virus [2013‑01]
C12N 2730/10121
. . . .
Viruses as such, e.g. new isolates, mutants or their genomic sequences [2013‑01]
C12N 2730/10122
. . . .
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes [2013‑01]
C12N 2730/10123
. . . .
Virus like particles [VLP] [2013‑01]
C12N 2730/10131
. . . .
Uses of virus other than therapeutic or vaccine, e.g. disinfectant [2013‑01]
C12N 2730/10132
. . . .
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent [2013‑01]
C12N 2730/10133
. . . .
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory [2013‑01]
C12N 2730/10134
. . . .
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein [2013‑01]